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REGULATION OF CELL ADHESION BY THE FERM 
PROTEINS, PTPN14 AND MERLIN 
 
Patty R. Dimarco Hewitt, B.S. 
 
Advisory Professor: Andrew B. Gladden, Ph.D. 
 
Cell-cell adhesion is critical for the control of tissue organization and homeostasis. A 
family of proteins that regulate cell-cell adhesions is the FERM (4.1 protein, Ezrin, Radixin, 
Moesin) domain-containing proteins. One FERM domain protein, the non-receptor tyrosine 
phosphatase PTPN14, is mutated or deleted in several human cancers suggesting that it may be 
involved in tumor development and/or progression. Additionally, the loss of the FERM domain 
protein Merlin is associated with tumor development and metastasis. Both PTPN14 and Merlin 
have been shown to localize and possibly regulate adherens junction (AJ) functions.  This work 
sought to determine if PTPN14 is required for the establishment of epithelial adhesion and 
polarity. Using mammalian epithelial cells as a model to test these hypotheses, we down-
regulated the tyrosine phosphatase, PTPN14. Decreased levels of PTPN14 increased E-cadherin 
membrane movement at cell contacts, disrupting cell contacts and abolishing E-cadherin 
localization during primordial lumen formation. In cells with established AJs and TJs, decreased 
levels of PTPN14 led to an increase in β-catenin Y654 phosphorylation, promoting increased 
membrane mobility of E-cadherin and subsequent destabilization of cell contacts.  This was 
dependent on PTPN14 phosphatase activity at β-cateninY654 opposing Src-mediated disruption 
of AJs. In cells that lacked PTPN14, for an extended time, I observed alterations in the 
morphology of the epithelial cells to a spindle morphology coupled with increased cell 
migration, transcriptional repression of E-cadherin and activation of Slug. Similar to the 
regulation of the AJ by PTPN14, we examined another FERM domain protein, Merlin, and 
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found that specific post-translational modifications in its unique N-terminal region regulate 
distinct AJ-mediated activities. Mutation of a single serine residue in the N-terminal region of 
Merlin blocked Merlin loading onto the AJ during early cell-cell adhesion formation. Disruption 
of Merlin AJ loading leads to actin disorganization and loss of contact inhibition of proliferation. 
Additionally, I found that phosphorylation of a second site in the N-terminal region of Merlin 
affects the release of the apical proteins, atypical protein kinase C (aPKC) and partitioning 
defective 3 (Par3), to the apical membrane for the development of functional TJs. Blocking this 
specific phosphorylation site disrupts the formation of functional polarized epithelia. From this, 
we see that distinct post-translational modifications of Merlin can alter its interaction with 
polarity proteins and thus Merlin function in regulating epithelial cell adhesion and polarity. 
Overall, these results indicate that mutation or post-translation regulation of FERM proteins 
could promote increased migration and invasion in cells altering normal epithelial development 
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Epithelial cell polarity and adhesion 
 Epithelia exist as sheets of adherent cells that create distinct physiological spaces in 
organisms1. The morphogenesis of epithelial tissue requires cell:cell interactions and cell polarity 
to shape organs and organisms2. For example, during neural tube formation, the neural plate and 
crest cells transition to a mesenchymal phenotype to induce movement and folding, which pulls 
in outer neural crest cells eventually forming a tube of cells that have switched adhesion 
functions which comprise the neural tube3. Development of tissues requires changes in both 
epithelial and mesenchymal-like functions and this can be regulated by epithelial to 
mesenchymal transition (EMT) where cells can switch from an epithelial state to a more 
mesenchymal state4,5 6-8.   The reverse biological process, mesenchymal-epithelial transition 
(MET) occurs in specific tissue developments such as kidney development9-12. The adult kidney 
originates from two embryonic mesodermal derivatives, the ureteric bud and metanephric 
mesenchyme. In the mammalian embryo, metanephric mesenchyme is induced by the ureteric 
bud to undergo a sequence of morphogenetic events that transition the mesenchyme to an 
epithelium to ultimately produce most of the tubules of the mature nephron13. Interestingly, 
reports have postulated that due to similar morphological properties between primary tumors and 
metastatic lesions, cells may restore certain epithelial characteristics through MET at a metastatic 
site14,15. In many solid tumor types, cancer cells hijack EMT and MET to acquire more migratory 
and invasive characteristics and eventually establish themselves at secondary sites16,17. 
Importantly, many of the same molecular events that drive EMT during embryonic 
developmental are the same events that mediate EMT during tumor progression18; therefore, 
understanding the processes that regulate EMT has significant clinical relevance at both the 
developmental and disease level. During epithelial morphogenesis, the junctional structures 
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known as adherens and tight junctions (AJs and TJs, respectively) that mediate cell adhesion and 
apicobasal polarity are regulated by EMT19.   	  
 Epithelial tissues are highly organized structures that use cell adhesion and polarity to 
help form epithelial tissues. For example, when intestinal epithelia is fully formed, sheets of 
polarized columnar epithelia are organized with an apical region which faces the lumen or outer 
surface and a basolateral region that is in contact with the basal lamina20,21 (Figure 1). Apical TJs, 
or zonula occludens, appear as a series of membrane appositions (or ‘kissing points’) that 
provide a continuous seal to facilitate adhesion between adjacent cells22. TJs have crucial 
functions by both serving as a barrier to the passage of molecules at cell:cell contacts and acting 
as a fence to maintain polarity by separating the apical and basolateral domains23-26. Over 40 TJ 
proteins have been identified including claudins27, occludins28, junctional adhesion molecules 
(JAMs)29, tricellulin30, zonulin31 and numerous scaffolding proteins32-34. Of these, claudins 
connect to the actin cytoskeleton through interactions with ZO-1, -2 and -3 , which are 
scaffolding proteins shown to play a critical role in the formation of TJs35 and in the maintenance 
of barrier function36. Disruption of TJ function is affiliated with a variety of pathological 
conditions such as ulcerative colitis37, irritable bowl syndrome (IBS), edema, cancer and blood-
borne metastasis34. While TJs are important for barrier and fence functions, their assembly is 
preceded by and dependent on the formation of the sub-apical AJ. The AJ is a dynamic calcium-
dependent structure that provides mechanical attachments between adjacent cells by initiating 
and stabilizing cell:cell contacts and regulating the actin cytoskeleton38,39. The core structural 
component of the AJ is the cadherin-catenin complex that consist of E-cadherin and the p120, α- 
and β-catenins. E-cadherin is a single-pass, transmembrane glycoprotein that forms homophilic 
interactions of epithelial AJ.  
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Figure 1. Schematic overview of adherens and tight junctions in simple columnar epithelia. 
The apical tight junctions (TJs) serve as a barrier for the passage of molecules at cell:cell 
contacts and are composed of the transmembrane proteins occludin, claudin and junctional 
adhesion molecules (JAMs). The scaffolding proteins, ZO-1, -2, and -3 link to transmembrane 
proteins and contribute to the TJ barrier function. The adherens junction (AJ) is just basal to the 
TJ and forms mechanical attachments between adjacent cells. At the core of the AJ is the 
cadherin-catenin complex that is composed of E-cadherin, p120-catenin and β-catenin. β-catenin 
associates with α-catenin that connects to the actin cytoskeleton. E-cadherin must be reinforced 
to the actin cytoskeleton through the cytoplasmic cadherin-catenin complex at the AJ for cells to 
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Classical cadherins, consisting also of N-, P- and R-cadherin40,41, have five characteristic 
extracellular cadherin repeat domains42 that form trans-cadherin interactions between 
neighboring cells to initiate formation of the AJ43,44. Once AJ contacts are formed, cadherins 
initially cluster and then spread laterally to strengthen cell:cell contacts45. In the majority of 
epithelial cells, E-cadherin is connected to the actin cytoskeleton by its interaction with 
catenins45 whose regulation can alter cell:cell contact strength and stability. The AJ interaction 
with the actin cytoskeleton is required in apical constriction during epithelial morphogenesis, 
tissue renewal and wound healing in multiple organisms42,44. Weakening of the AJ, by loss of E-
cadherin or catenins, can alter other cell adhesions structures, including the TJ, which can 
compromise the overall integrity of cells by reducing cell adhesion46,47. Abnormal adhesion or 
loss thereof can lead to a host of chronic disease states that can progress to cancer, through 
aberrant signaling from the AJ41. In addition to the core AJ proteins, numerous other proteins 
interact with or localize near the AJ, helping to regulate cell adhesion and transmit signals from 
the cell surface to the actin cytoskeleton. One such group of proteins that link cytoskeletal 
signals to membrane proteins is the ERM (Ezrin, Radixin and Moesin) protein family48-51.  
 
ERM proteins 
 Originally named for its founding members Ezrin, Radixin and Moesin, ERM proteins 
are a highly evolutionarily conserved family of proteins important for regulating cell adhesion 
and membrane dynamics48. ERM proteins contain an amino-terminal FERM domain and a 
carboxy-terminal actin-binding domain separated by an extended alpha-helical linker domain52 
(Figure 2A). Through their FERM domain, ERM proteins can bind directly to adhesion 
molecules53,54 or indirectly link to the plasma membrane55,56. A major structural property of  
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Figure 2. Domain structure of ERM family members. A) The ERM proteins are a highly 
evolutionarily conserved protein family and are named after the founding members, ezrin, 
radixin and moesin. ERM proteins contain an N-terminal membrane anchor FERM domain, an 
extended α-helical domain and a C-terminal actin-binding domain. Merlin belongs to the ERM 
protein family although it lacks the C-terminal actin-binding domain. The first 17 amino acids at 
the N-terminal region (NT) of Merlin are unique among ERM molecules. B) PTPN14 contains 
an amino terminal FERM domain that makes it a close family member to the ERM proteins. The 
carboxy terminal catalytic phosphatase domain (PTP) is connected to the FERM domain via an 
unstructured central linker region. Protein model provided by Dr. Stefan Arold (KAUST). 
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ERM molecules is the ability to self-associate by a proposed intramolecular head-to-tail 
interaction between the amino- and carboxy-terminal domains52.  
Although ERMs are believed to have overlapping functions, studies have uncovered 
critical roles for individual ERMs in vivo57-60. Of interest is the similar role for ERM proteins in 
establishing apical identity in intestinal lumen morphogenesis in C. elegans and mouse. The only 
C. elegans ERM orthologue, erm-1, and mouse Ezrin maintain the apical:junctional interface 
during early lumen morphogenesis by repositioning from the junctional region to the apical 
surface as polarity is established35,36. In a similar manner, the developing intestines undergo a 
switch in Ezrin distribution as cells differentiate and migrate up the villus axis61. Although ERM 
function is important for junctional remodeling during lumen morphogenesis, studies do not 
suggest that these proteins are required for AJ stability in established epithelia.  Two proteins 
closely related to the ERM protein family that localize with and influence the AJ are the tyrosine 
phosphatase, PTPN14, and the tumor suppressor, Merlin. 
 
The tyrosine phosphatase, PTPN14 
The FERM-domain containing protein, PTPN14, also known as Pez, PTP36 and PTPD2, 
is a non-receptor tyrosine phosphatase that is expressed in multiple tissues62. PTPN14 is a 
member of the ERM protein family containing a N-terminal FERM domain; however, it is 
unique from other ERM family members because of its C-terminal phosphatase activity63,64 
(Figure 2B). Loss-of-function studies indicate a requirement for PTPN14 in the developing 
zebrafish heart and brain65. Interestingly, PTPN14 gain-of-function induces EMT and increases 
canonical transforming growth factor beta (TGFβ) signaling in Madin-Darby Canine Kidney 
(MDCK) cells65, suggesting that PTPN14 may harbor tumor suppressor and oncogenic functions. 
PTPN14 mutations occur in a subset of CRC patients, but mainly result in truncated proteins 
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with reduced phosphatase activity66. PTPTN14 is shown to regulate tyrosine phosphorylation of 
the AJ protein, β-catenin, but the residue at which PTPN14 dephosphorylates β-catenin is 
unknown67 (Figure 3) . How and whether this activity impacts β-catenin signaling or AJ-
mediated adhesion is not known. In addition, evidence suggests that PTPN14 also regulates p130 
Crk-associated substrate (Cas) phosphorylation in CRC, which may influence the migratory and 
proliferative properties of these cells68. Recently PTPN14 has been implicated in the direct and 
indirect regulation of signaling pathways, including the TGFβ and Hippo signaling pathways65. 
The TGFβ pathway is known to induce EMT in a number of cell lines and tissues69,70. In addition 
to TGFβ signaling, PTPN14 directly interacts with and negatively regulates YAP, a core 
component of the Hippo signaling pathway, in a phosphatase-independent manner	  71-73. The 
Hippo pathway has also been implicated in inducing EMT and regulation of proliferation74.  
 
The Nf2 tumor suppressor, Merlin 
Mutations of the neurofibromatosis type 2 (NF2) gene have been identified in multiple 
cancer types, including breast and liver cancer, malignant mesothelioma, sporadic meningiomas 
and schwannomas75-79. Merlin is the protein product of the NF2 tumor suppressor gene and 
belongs to the ERM protein family. Merlin protein has a N-terminal FERM domain that is highly 
homologous to Ezrin but unlike Ezrin and other ERM family members, Merlin has an unique 
unstructured N-terminal region made up the first 17 amino acids and lacks the C-terminal actin-
binding site common to ERM proteins80,81 (Figure 2A). Despite the absence of this C-terminal 
actin-binding site, Merlin has been shown to be necessary to link membrane proteins and the 
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Figure 3. Overview of junctional and polarity proteins. The apical scaffolding protein, ZO-1, 
is localized at the tight junctions (TJs) in cells. The TJ is positioned just apical to the adherens 
junction (AJ) that is composed of a cadherin-catenin complex consisting of E-cadherin linked to 
α-, β- and p120-catenins. β-catenin associates with α-catenin that connects to the actin 
cytoskeleton. The FERM protein, PTPN14 dephosphorylates β-catenin at an unknown tyrosine 
residue. Merlin associates with α-catenin via its N-terminal tail, linking it to the apical proteins, 
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developing mouse is embryonic lethal in mice86 while heterozygous Merlin knockout mice 
(Nf2+/-) develop a series of highly metastatic tumors87. These data collectively suggest that 
Merlin may act as a tumor suppressor in multiple cell types. Numerous studies have uncovered 
three main mechanisms of Merlin tumor inhibition including contact-dependent growth 
inhibition85,88, decreased proliferation89-92, and increased apoptosis93, but how Merlin coordinates 
or separately regulates these mechanisms is not fully understood.  
Merlin has a direct role in cell polarity by its restriction of apical Ezrin which guides 
proper spindle orientation94 resulting in the formation of a single central lumen in epithelial 
cysts95-97. However, many uncertainties remain about the regulation of Merlin activity during cell 
junction formation and the establishment of apicobasal polarity.  Recent studies address this by 
identifying that Merlin fails to associate with the AJ and does not localize to cell:cell contacts 
when it lacks the first 17 amino acids of its N-terminus (Nf218-595)98. In addition, expression of 
Nf218-595 compromised the formation of functional TJs through Merlin’s inability to associate 
with the AJ protein, α-catenin84. Complete loss of Merlin also inhibits TJ formation and causes 
mis-localization of the polarity protein, atypical protein kinase C (aPKC)84. aPKC belongs to the 
PAR (Par3/Par4/aPKC) complex localized at the TJ in established epithelia99. Similarly, when 
aPKC kinase activity is eliminated, the formation of functional TJs is blocked and cell polarity is 
altered100, suggesting that mis-localization of aPKC affects cell membrane organization. Given 
the similar observations between loss of aPKC or loss of the N-terminal region of Merlin, it is 
possible that aPKC or another member of the PAR complex may play a role in regulating 
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The polarity proteins, Par3 and aPKC 
 Originally identified in a C. elegans screen for its importance in spatial restriction of the 
cytoskeleton and spindle asymmetry101, the PAR protein complex includes Par3, Par6, Cdc42, 
and the serine/threonine kinase aPKC102. Genetic studies in Drosophila established an important 
role for the PAR complex in the development and maintenance of polarity in epithelial cells103-105. 
Importantly, the PAR complex is required for proper polarity in mammalian cells106. Recent 
work has indicated that the PAR complex is a crucial signaling module that regulates 
polarization by integrating external and internal inputs to maintain homeostasis of normal cells. 
The complex components of the apical polarity complex are shown to be involved in tumor 
initiation and progression, both as regulators of oncogenic and tumor suppressor pathways, 
highlighting the importance of the PAR complex not only in tissue maintenance but also in 
inhibiting tumor formation107.  
Par3 is a highly conserved polarity protein that has important roles in establishing 
apicobasal polarity108. When Par3 expression is lost, epithelial cells do not form electrically 
resistant TJs, resulting in “leaky” junctions109. How Par3 contributes to proper TJ formation is 
not known. Current reports suggest that during the early stages of junction formation, Merlin is 
essential for linking Par3 to the AJ84. After formation of the AJ, Par3 is localized to the apical 
domain for formation of TJs. How Par3 is transitioned from the AJ to the TJ remains undefined. 
In addition, what role Merlin has in the regulation of Par3 localization to the apical domain is 
unknown. One potential method of regulation could be through a role of Merlin in promoting the 
association of Par3 with aPKC.  
 Atypical protein kinases C is a member of the protein kinase C family of 
serine/threonine kinases whose activation is not dependent on diacylglycerol or calcium, but 
instead are controlled by the PAR protein complex110. Two aPKC genes have been identified in 
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mammals, aPKCλ/ι111 and aPKCζ112, which produce two different protein products that function 
as part of the PAR protein complex. To date, there is no evidence of the two isoforms having 
different functions in their roles as regulators of epithelial cell polarity, although their 
localization in the mouse epidermis is different suggesting that they may have spatially distinct 
mechanisms113. aPKC genomic amplification is seen in human cancers, including prostate, 
gastric, breast and ovarian cancers114,115. Interestingly, blocking aPKC kinase activity alters cell 
polarity and inhibits the formation of TJs, indicating that active aPKC kinase and Par3 
localization are essential for proper TJ formation116. Furthermore, loss of Merlin causes mis-
localization of aPKC away from the cell membrane, which could have an effect on cellular 
membrane organization84. These data suggest the existence of a key regulatory pathway in cell 
polarity and adhesion that may be coordinated by the NF2 tumor suppressor protein, Merlin. 
Further understanding of the pathways that govern cell adhesion and polarity has the potential to 
uncover new therapeutic targets not only for epithelial tumors, but also for Schwann cell tumors 
that develop in NF2 patients.  
 
Epithelial cell polarity plays a vital role in a number of biological processes, such as cell 
adhesion117,118, division119-123 and migration124-126. Defects in apicobasal polarity and adhesion 
are intimately linked to tissue disorganization resulting in tumorigenesis and ultimately, 
metastatic disease. The FERM domain protein family is widely known to play a role in 
regulating cell adhesion61,127,128. This thesis focuses on two FERM domain proteins, PTPN14 and 
Merlin, whose loss is observed in several human cancers.  
The work in this thesis describes a new function that I have uncovered for a phosphatase-
dependent role of PTPN14 in the regulation of AJ-mediated adhesion in intestinal lumen 
formation. Cells with decreased PTPN14 failed to form a lumen in 3D due to the inability to 
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form functional AJs and TJs. In cells with established AJs and TJs, decreased PTPN14 caused an 
increase in β-catenin-Y654 phosphorylation and E-cadherin membrane mobility leading to 
destabilization of cell contacts. My data demonstrates that PTPN14 phosphatase activity at β-
catenin-Y654 opposes the Src kinase. Interestingly, when cells are exposed to decreased PTPN14 
for an extended amount of time, the morphology of cells in culture changes from a classic 
epithelial cobblestone appearance to a spindle-cell morphology. This morphologic change is 
accompanied by loss of collective cell migration, loss of contact inhibition, transcriptional 
repression of E-cadherin and activation of Snail2/Slug potentially by Notch signaling from the 
AJ. This research highlights a novel role for PTPN14 as an important mediator of cell:cell 
adhesions and cell polarity through stabilization of essential epithelial features.  
Additionally, the work described herein focuses on the step-wise post-translational 
modification of the FERM domain protein and tumor suppressor, Merlin, by aPKC to facilitate 
establishment of epithelial junctions and apicobasal polarity. When a single serine 
phosphorylation of the extreme N-terminal region of Merlin is blocked, Merlin is not loaded to 
the AJ during junctional development causing actin disorganization and loss of contact inhibition 
of proliferation. A subsequent phosphorylation event releases the polarity proteins, aPKC and 
Par3, from the AJ to the apical membrane for formation of functional TJs and proper epithelial 
polarity. This illustrates how post-translational modifications of Merlin can alter its protein 
function and interaction with polarity proteins to promote Merlin-mediated regulation of 
epithelial adhesion and polarity coordination.  
In summary, my work shows the importance of FERM domain proteins in the 
development of functional epithelial cell adhesion and in the establishment of apicobasal polarity. 
My observations also indicate a critical role for FERM domain proteins in the maintenance of 
tissues to avoid alterations of epithelial cell adhesion that lead to tumor initiation and/or 
	   14	  
progression. Cell adhesion is critical to maintain a protective epithelial barrier from bacterial and 
microbial infiltration. Consequently, altered cell adhesion can cause barrier defects that lead to 
inflammatory responses that promote tumor growth129. Therefore, increasing the understanding 
of the roles of PTPN14 and Merlin in controlling the establishment of cell adhesion and the 





























































MATERIALS AND METHODS 
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Cell Culture  
Human Caco-2BBE cells were cultured in DMEM (Dulbecco’s Modified Eagle’s Medium) 
containing 10% fetal bovine serum (FBS).  Production of lentiviral expression vectors used for 
targeted knockdown (pLKO.1) or over-expression (pCDH) was performed by transfecting 293T 
cells with the respective construct and the packaging vectors, ΔVPR and VSVG. Twenty-hours 
after lentiviral infection, cells were selected with puromycin (pLKO.1) and/or hygromycin 
(pCDH).  
For 3D culture, following trypsin treatment, cells were resuspended in media and passed 
through a 40µm-filter to obtain single-cell suspension. Cells were spun down for 5 minutes at 4o, 
then resuspended in 250µl of matrigel/collagen media (5% Matrigel, 0.02M Hepes, 1mg/ml 
Collagen 1) to a final concentration of 4x104 cells per milliliter. Cell suspensions were plated in 
an 8-well chamber slide, allowed to solidify for 30 minutes at 37oC, and then topped with media. 
Cells were re-fed after two days then collected on day six. The pharmacological inhibitor, 
Dasatinib, was added directly to the media at a concentration of 150nM two times per day. 
 The hanging drop assay was performed as previously described84,130. Caco-2 cells were 
trypsinized to a single cell suspension using a 40µm filter. Cells were collected at a density of 
4x106 cells, spun down and resuspended in 2mL DMEM/10% FBS. 50µl drops of each cell type 
were hung on the bottom of a 35mM dish and placed in a 37oC incubator. Drops were pipetted 
25x at one-hour intervals for three hours and then counted for 1-2 cells/clump, 3-6 cells/clump or 
7+ cells/clump. 
 
Western Blot and Immunoprecipitation (IP) 
For Western blots, cells were lysed using RIPA lysis buffer (50 mM Tris at pH 7.4, 1% 
Triton X-100, 1% SDS, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
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1 mM PMSF, 1 mM Na3VO4, 1 mM sodium fluoride, 1 mM β-glycerophosphate, 10 µg/mL 
aprotinin, 10 µg/mL leupeptin) followed by a brief sonication. Cell debris was cleared by 
centrifugation. Lysates were quantified by Bradford assay, separated by SDS-PAGE and 
transferred to PVDF membrane.  Membranes were blocked in 5% milk for 1 hour and incubated 
with primary antibody overnight at 4oC diluted in 1% milk.  
 For IPs, cells were lysed in Triton lysis buffer (1% Triton X-100, 50mM Tris-HCl pH 7.4, 
140mM NaCl, 1mM EDTA, 1mM EGTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM sodium fluoride, 
1 mM β-glycerophosphate, 10 µg/mL aprotinin, 10 µg/mL leupeptin), followed by one round of 
sonication. Cell debris was cleared by centrifugation. Lysates were quantified using the Bradford 
assay. Protein lysates were diluted in Tween 20 buffer (50mM HEPES pH 8, 150mM NaCl, 2.5 
mM EDTA, 2.5 mM EGTA, 0.1% Tween 20, 1 mM PMSF, 1 mM Na3VO4, 1 mM sodium 
fluoride, 1 mM β-glycerophosphate, 10 µg/mL aprotinin, 10 µg/mL leupeptin) and incubated 
with Protein A sepharose beads then incubated with primary antibodies overnight at 4oC diluted 
in 1% milk. The precipitated complexes were washed with Tween 20 buffer 4 times then 
resuspended in protein loading buffer, boiled and loaded onto SDS-PAGE gels.  
 Primary antibodies used for Western blot, IP and/or immunofluorescence (IF) in this 
work were: Pez/PTPN14 (1:500 for IF and 1:750 for Western blotting, G-20, Santa Cruz), ZO-1 
(1:500 for IF and Western blotting, 617300, Invitrogen), E-cadherin (1:1000 for IF and Western 
blotting, 610182, BD Biosciences), α-catenin (1:1000 for Western blotting, 610193, BD 
Biosciences), p120 (1:2000 for Western blotting, 610133, BD Biosciences), β-catenin (1:2000 
for IF and Western blotting, 610153, BD Biosciences),  β-catenin (Tyr-654), phospho-specific 
(1:500 for IF and Western blotting, CP4021, ECM Biosciences), β-catenin (Tyr-489), phospho-
specific (1:500 for Western blotting, CP2961, ECM Biosciences), β-catenin (Tyr-142), phospho-
specific (1:500 for IF and Western blotting, CP1081, ECM Biosciences), Ezrin (1:100 for IF, 
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357300, Invitrogen), c-Myc (1:250 for Western blotting, SC-40, Santa Cruz), NF2/Merlin, C-
terminal (1:1000 for IF and Western blotting, C-18, Santa Cruz), NF2/Merlin, N-terminal 
(1:1000 for IF and Western blotting, A-19, Santa Cruz), ZEB-1 (1:1000 for Western blotting, H-
102, Santa Cruz), Snail2/Slug (1:500 for Western blotting, C19G7, Cell Signaling), Vimentin 
(1:1000 for Western blotting, 3932, Cell Signaling), Smad4 (1:500 for IF, 9515, Cell Signaling), 
total-YAP (1:1000 for IF, 4912, Cell Signaling), β-tubulin (1:20,000 for Western blotting, T7816, 
Sigma). For IF, filamentous actin was used to label Phalloidin (1:200, Alexa Fluor 488 and 568, 
Invitrogen) and nuclei were labeled with 4′6′-diamidino-2-phenylindole (DAPI). 
 
Plasmids 
pLKO.1 lentiviral plasmids targeting human PTPN14 were obtained from Open 
Biosystems (Clone ID NM_005401.3-3772s1c1 and NM_005401.3-754s1c1). The human 
PTPN14 cDNA was ordered from Thermo Scientific (Clone ID 8143806). The p-GEM-T 
cloning vector was used to PCR out the human PTPN14 fragment into the pCDH-CMV-MCS-
EF1 lentiviral mammalian expression vector (System Biosciences). sh-RNA resistance was 
conferred by making six silent mutations in the respective shRNA targeting sequence. The 
following QuickChange primers were used to mutate C1121 to M and make the PTPN14 
catalytic-dead mutant: 5’-CATCGTGTCCACTCTAGTGCTGGGGTGG-3’ (forward primer) 
and 5’-CCACCCCAGCACTAGAGTGGACCACGATG-3’ (reverse complement). The 
following QuickChange primers were used to mutate Y654 to F and make the non-
phosphorylatable β-catenin mutant: 5’-GGAATGAAGGCGTGGCAACATTCGCAGCTGCTG-
3’ (forward primer) and 5’-CAGCAGCTGCGAATGTTGCCACGCCTTCATTCC-3’ (reverse 
complement). N-terminal Myc epitope tags were added to β-cateninWT and β-cateninY654F by 
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cloning into the pJ3M vector. All constructs were subcloned into the pCDH-CMV-MCS-EF1 
mammalian lentiviral expression vector (System Biosciences).  
The human Nf2 shRNA targeting sequence 5’-AGGAAGCAGCCCAAGACATTC-3’ 
was inserted into the pLKO.1 lentiviral plasmid. The pCDNA3 cloning vector was used to PCR 
out the human Nf2 full-length fragment into the pCDH-CMV-MCS-EF1 lentiviral mammalian 
expression vector (System Biosciences). sh-RNA resistance was conferred by making three silent 
mutations in the respective shRNA targeting sequence. The following QuickChange primers 
were used to mutate S7 to A to make the Merlin non-phosphorylatable mutatant: 5’- 
CCGGAGCCATCGCTGCTCGCATGAGCTTC-3’ (forward primer) and 5’- 
GAAGCTCATGCGAGCAGCGATGGCTCCGG-3’ (reverse complement). The following 
QuickChange primers were used to mutate S10 to A to make the Merlin non-phosphorylatable 
mutant: 5’-CCATCGCTTCTCGCATGGCCTTCAGCTCACTCAAGA-3’ (forward primer) and 
5’- TCTTGAGTGAGCTGAAGGCCATGCGAGAAGCGATGG-3’ (reverse complement). The 
following QuickChange primers were used to mutate S12 to A and make the Merlin non-
phosphorylatable mutant: 5’- CTTCTCGCATGAGCTTCGCCTCACTCAAGAGGAAGC-3’ 
(forward primer) and 5’- GCTTCCTCTTGAGTGAGGCGAAGCTCATGCGAGAAG-3’ 
(reverse complement). The following QuickChange primers were used to mutate S13 to A and 
make the Merlin non-phosphorylatable mutant: 5’-
GCATGAGCTTCAGCGCCCTCAAGAGGAAGCAG-3’ (forward primer) and 5’- 
CTGCTTCCTCTTGAGGGCGCTGAAGCTCATGC-3’ (reverse complement). The S7/10/12/13 
to A Merlin non-phosphorylatable mutant was generated in a stepwise process using the 
QuickChange primers for each S to A mutation. The pFlex cloning vector was used to add an N-
terminal flag tags to the Nf2 fragment. 
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Quantitative reverse-transcription-PCR 
 Total RNA was isolated from cells using Trizol followed by chloroform extraction and 
2µg RNA was used for first strand cDNA synthesis using the SuperScript® First-Strand 
Synthesis System (Invitrogen). The two primer sequence sets for human PTPN14 were 5’-
ATGCCTTTTGGTCTGAAGCTC-3’ (forward primer 1), 5’-CCCTGTGCTTTCCACCGAC- 3’ 
(reverse complement 1), 5’-AGCTGCGAGAGACGCACTA-3’ (forward primer 2) and  
5’-GCTCATTAGCGAATTTGTCCAGA-3’ (reverse complement 2). The two primer sequence 
sets used for human E-cadherin were 5’-CGAGAGCTACACGTTCACGG-3’ (forward primer 
1), 5’-GGGTGTCGAGGGAAAAATAGG-3’ (reverse complement 1),  
5’-ATTTTTCCCTCGACACCCGAT-3’ (forward primer 2), and  
5’-TCCCAGGCGTAGACCAAGA-3’ (reverse complement 2). The two primer sequence sets 
for human CDH2/N-cadherin were 5’-TCAGGCGTCTGTAGAGGCTT-3’ (forward primer 1), 
5’-ATGCACATCCTTCGATAAGACTG-3’ (reverse complement 1),  
5’-AGCCAACCTTAACTGAGGAGT-3’ (forward primer 2) and  
5’-GGCAAGTTGATTGGAGGGATG-3’ (reverse complement 2). The primer sequences used 
for human Snail1 were 5’-TCGGAAGCCTAACTACAGCGA-3’ (forward primer) and 5’-
AGATGAGCATTGGCAGCGAG-3’ (reverse complement). The primer sequences used for 
human Snail2/Slug were 5’-CGAACTGGACACACATACAGTG-3’ (forward primer) and 5’-
CTGAGGATCTCTGGTTGTGGT-3’ (reverse complement). The primer sequences used for 
human BIRC3 were 5’-AGAGAGGAGCAGAGATGGAGCA-3’ (forward primer) and 5’-
TTTGTTCTTCCGCATTAGTGC-3’ (reverse complement). The primer sequences used for 
human CTGF1 were 5’-GGGCCTCTTCTGCGATTTC-3’ (forward primer) and 5’-
ATCCAGGCAAGTGCATTGGTA-3’ (reverse complement). The primer sequences used for 
human AREG were 5’-GTGGTGCTGTCGCTCTTGATA-3’ (forward primer) and 5’-
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CCCCAGAAAATGGTTCACGCT-3’ (reverse complement). The primer sequences used for 
mammalian GAPDH were 5’-ACAACTTTGGTATCGTGGAAGG-3’ (forward primer) and 5’- 
GCCATCACGCCACAGTTTC-3’ (reverse complement). PCR was performed using the 
7900HT Sequence Detection System (Applied Biosystems) with SYBR green quantification. 
Gene expression was normalized to GAPDH expression levels.  
 
In vitro kinase assay 
 100 ng of GST-aPKC-ζ (Echelon Biosciences) was mixed with Flag-Merlin or Flag-
Ezrin produced in Sf9 cells or NT-Merlin, NT-Merlin 12/13A, NT-Merlin 7/10/12/13A produced 
by IVTT in kinase assay buffer (25 mM MOPS, pH 7.2, 12.5 mM β-glycerol-phosphate, 25 mM 
MgCl2, 5 mM EGTA, 2 mM EDTA and 0.25 mM DTT).  Following mixing on ice 0.25 mM of 
ATP and 10 mCi gamma-32P-ATP was added to the kinase reaction and incubated at 30°C for 20 
minutes with occasional mixing.  The reaction was stopped by addition of 6x SDS sample buffer 
and then boiled for 3 minutes.  The kinase reaction was loaded on a SDS-PAGE gel and 
following electrophoresis the gel was stained with Coomassie, destained, dried and exposed to 
film. 
 
Reverse Phase Protein Array (RPPA)  
 Cells were lysed using the following lysis buffer: 1% Triton X-100, 50mM HEPES, pH 
7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM 
Na3VO4, 10% glycerol, 1 mM PMSF, 1 mM Na3VO4, 1 mM β-glycerophosphate, 10 µg/mL 
aprotinin, 10 µg/mL leupeptin. Cell debris was cleared by centrifugation. Lysates were quantified 
by Bradford Assay and mixed with 4 x SDS sample buffer without bromophenol blue (40% 
Glycerol, 8% SDS, 0.25M Tris-HCL, pH 6.8. with 2-mercaptoethanol at 1/10 of the volume) 
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with a final mixture of 3 parts of cell lysate mixed with one part of 4 x SDS sample buffer. 
Duplicate control (scr), early (93C), middle (93B) and late (93A) PTPN14 depleted cells were 
submitted to the MD Anderson RPPA Core Facility and were stained for 285 unique antibodies 
and analyzed on Array-Pro then by supercurve Rx64 3.1.1. Samples were probed with the 
antibodies using a CSA amplification approach and visualized by DAB colorimetric reaction. 
The heatmap was generated in Cluster 3.0 as a hierarchial cluster using Pearson Correlation and 
shows overall patterns of protein levels.  
 
Immunofluorescence and Live-Cell Imaging 
In 3D culture, Caco-2 cells were fixed in 3.7% Formalin in cytoskeletal buffer (CB) 
[10mM 2-(N-morpholino)-ethanesulfonic acid sodium salt (MES) at pH 6.1, 138 mM KCl, 3mM 
MgCl2, 2mM EGTA] for 20 minutes at room temperature, briefly washed in PBS and 
permeabilized in 0.5% Triton/PBS for 20 minutes at room temperature. After rinsing with PBS, 
cells were washed with 100mM Glycine/PBS for 3X15 minutes and blocked for one hour in 
PBS-T/0.2% Triton/1% BSA/10% goat serum. Primary antibodies were incubated overnight in 
blocking buffer at 4oC. After a brief wash with PBS-T, cells were incubated in secondary 
antibodies for one hour at room temperature. In 2D culture, Caco-2 cells were grown on glass 
coverslips to confluence. Cells were fixed with ice-cold methanol-acetone for 10 minutes at -
20oC and then treated with 1.5N HCl for 10 minutes at room temperature. After blocking with 
PBS-T/10% HISS for 30 minutes, cells were incubated with primary antibody overnight at 4oC. 
After washing with PBS-T, cells were incubated with secondary antibodies diluted in PBST/10% 
HISS for 1 hour. All labeled cells were visualized with a Nikon A1 laser scanning confocal 
microscope and processed using the Nikon-Elements software (Nikon). 3D images were 
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deconvolved to remove excess background with the AutoQuant X3 software (Media 
Cybernetics).  
For live-cell imaging and FRAP, Caco-2BBE cells were grown on a one compartment 
35mm glass-bottom dish to confluence in DMEM supplemented with 10% FBS then switched to 
DMEM with no phenol red supplemented with 10% FBS before imaging. The cells were 
visualized using a Perkin Elmer spinning disc confocal microscope fitted with a Hamamatsu 
EMCCD 9100-13 camera and a 60X water objective. An attached control chamber allowed for 
temperature and CO2 maintenance to preserve the cells in culture. Improvision Volocity analysis 
software (Perkin Elmer) was used to acquire live-cell imaging and FRAP data. Z-stacks were 
acquired every thirty seconds for five minutes. Imaging configuration was optimized for high 
fluorescence intensity per pixel. For FRAP acquisition, a region of interest (ROI) was selected by 
drawing a circular region of the same size at a single cell:cell contact and around a region in the 
background as a control. To provide steady-state fluorescence intensity, a minimum of three pre-
bleach images at approximately one frame per second was taken before photo-bleaching. Laser 
intensity was set at 100% for the photo-bleaching event. Once photo bleaching occurred, 
multiple time points were obtained during the early stages of recovery and each FRAP recovery 
curve was collected for 10 minutes post-bleach. The FRAP curves were fitted with one-phase 
exponential equations. To remove excess background, live-cell imaging data was deconvolved 
using the AutoQuant X3 software (Media Cybernetics).  
 
Image Processing and Analysis 
Live-cell imaging snapshots presented in figures 9 and 10 were processed using 
Bitplane’s Imaris software. Individual GFP spots were tracked and each was less than 0.3µm in 
size and traveled a distance of no more than 5µm. Quantitative analysis of xyz planes were 
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acquired through cropping a single cell:cell contact in 3D and using the mean values for the 
horizontal (x) plane +/- standard deviation. Five separate images were analyzed per cell type and 
representative images are shown in figures 9 and 10. 
 







































REGULATION OF LUMEN FORMATION AND CELL ADHESION BY THE 
TYROSINE PHOSPHATASE, PTPN14 
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Introduction 
Organization of epithelial tissues requires controlled communication between 
neighboring cells to coordinate tissue development and morphogenesis131. Cells utilize numerous 
signaling pathways to interact with neighboring cells and to respond to external cues and changes 
in the extracellular matrix132. A primary means of direct cell communication is through 
specialized cell:cell contacts which aid in organizing cells in a polarized fashion. Cell 
polarization gives rise to accurate spatiotemporal responses to signals that come from 
neighboring cells and the surrounding microenvironment 133. The formation of polarized cell 
layers largely depends on cell adhesion and the polarity complexes known as adherens and tight 
junctions (AJ and TJ, respectively). The AJ is a dynamic calcium-dependent structure that 
promotes the physical association of adjacent cells’ cytoskeletons134,135. At the core of the 
epithelial AJ, E-cadherin acts as the main adhesive transmembrane protein136-138. E-cadherin 
binds directly to β-catenin, a linker to α-catenin that binds actin filaments thereby connecting 
cadherins to the actin cytoskeleton139-144. The AJ interaction with the actin cytoskeleton is critical 
for regulating mechanical cues that drive cell polarity, directionality of cell migration and speed 
of migration during collective cell migration46,145. Proper collective cell migration is necessary 
for morphogenesis, tissue renewal and wound healing in multiple organisms46,47,146-148. 
Consequently, weakening of the AJ by down regulation of E-cadherin or deletion/mutation of the 
catenins, can compromise the formation of other cell adhesion structures, including the TJ, and 
establishment of cell polarity84. Interference of the coordinated formation of cell contacts and 
polarity can disrupt overall cellular integrity leading to loss of tissue function and disease46,47.  
Cadherin-mediated adhesion is regulated on numerous levels throughout the cell. E-
cadherin and β-catenin initially associate in the endoplasmic reticulum, and this complex is then 
trafficked to the plasma membrane149. Initial binding of E-cadherin extracellular domains on 
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neighboring cells promotes assembly of the E-cadherin and β-catenin complex with α-catenin, 
linking this primordial AJ to the actin cytoskeleton150,151. Association with the actin cytoskeleton 
partially immobilizes the AJ which is thought to aid in local AJ complex clustering, in turn 
strengthening the AJ- mediated adhesion between adjacent cells152-155. Cadherin-mediated 
adhesion can also be regulated directly by phosphorylation of both the cadherins and catenins156. 
Tyrosine phosphorylation of E-cadherin alters its binding affinity for p120- and β-catenin in 
endothelial cells157. 
Serine/threonine phosphorylation of p120-catenin protects E-cadherin from endocytosis, 
subsequently stabilizing the AJ 158. Tyrosine phosphorylation of β-catenin can alter cell adhesion 
through disruption of β-catenin-α-catenin binding or by altering the adhesion properties of the E-
cadherin/β-catenin complex. One such tyrosine kinase that regulates E-cadherin-mediated 
adhesion at the AJ is Src159,160. The pp60c-src protein kinase phosphorylates β-catenin at Y86 and 
Y654, but only phosphorylation at Y654 alters E-cadherin-mediated adhesion161.  The c-Src 
proto-oncogene is connected to the initiation and progression of cancer in numerous tissues 
including breast, lung, colon, pancreas and skin162. Although much work has been done to extend 
our knowledge of the Src family of kinases in regulating the AJ in disease and cancer, relatively 
little is known about the opposing phosphatases that regulate Src-mediated tyrosine 
phosphorylation at the AJ.  
PTPN14, also known as Pez, PTP36 and PTPD2, is a non-receptor tyrosine phosphatase64 
that is expressed in multiple tissues65 and is significantly downregulated in colorectal cancer 
(CRC) (Oncomine microarray data). PTPN14 mutations are found in a subset of CRC patients 
with the majority of these mutations resulting in truncated proteins with reduced phosphatase 
activity66. PTPN14 belongs to the FERM (Band 4.1, Ezrin, Radixin and Moesin) domain family 
of protein tyrosine phosphatases (PTPs) and is characterized by the conserved N-terminal FERM 
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domain and a C-terminal PTP domain divided by a flexible linker region63,64. The FERM domain 
family of proteins coordinates and regulates extracellular signals from the membrane to the 
cellular cytoskeleton127. PTPN14 is thought to regulate tyrosine phosphorylation of the AJ 
protein, β-catenin; however, the specific tyrosine phosphorylation site(s) regulated by PTPN14 
are not known67. How and whether PTPN14 activity on β-catenin influences β-catenin signaling 
or AJ-mediated adhesion and tissue morphogenesis remains elusive. Considering the down 
regulation and/or mutation of PTPN14 in human disease as well as its possible role at the AJ, we 
examined the endogenous function of PTPN14 in polarized intestinal epithelial cells.  Here we 
describe a mechanism of regulation of adhesion and apicobasal polarity by the protein tyrosine 
phosphatase, PTPN14, and investigate its endogenous function in stabilization of the E-
cadherin/β-catenin complex at the AJs.  
 
Results 
PTPN14 localizes to cell contacts during epithelial junction development 
Previous work revealed a capacity for PTPN14 to regulate both proliferation and 
migration pathways, but the mechanism for this activity has remained unclear65,67,72,163. To 
examine endogenous function(s) of PTPN14, we first sought to determine the localization pattern 
of PTPN14 in the well-established Caco-2BBE (hereafter referred to as Caco-2) intestinal 
epithelial cell line94. Caco-2 cells are a well-documented system to study apicobasal polarity 
during epithelial cyst formation94,95. To determine the localization of PTPN14 during lumen 
formation, we performed 3D lumen formation assays. When the primordial lumen is forming at 
the 2-cell stage, PTPN14 lines the cells on the periphery and at the apical (inner) surface (Figure 
4A). E-cadherin has a similar staining pattern, but with an increase in protein localization at 
either end of the primordial lumen (Figure 4A). Similar to calcium-treated Caco-2 monolayers, 
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PTPN14 localizes with E-cadherin and ZO-1 in mature wild-type cysts (Figure 4B). E-cadherin 
localizes to the basolateral surface and at lateral cell-cell contacts while ZO-1 lines the apical 
(luminal) surface. Collectively, these data indicate that PTPN14 localizes with AJ and TJ 
proteins during cell contact formation and during ex vivo lumen development.  
In line with previous observations, we found that PTPN14 localizes to cell:cell contacts 
(Figure 4C, lower panel). To determine if PTPN14 localizes with specific cell contacts during 
junctional development, we performed a calcium switch assay164-168. Cells placed in low-calcium 
media, which disrupts cadherin-mediated adhesion, (Figure 4C, top panel) show punctate co-
localization of PTPN14, E-cadherin and the TJ protein ZO-1, indicative of spot (nascent) AJ. 
Following calcium depletion, addition of calcium triggers cell junction maturation and 
organization of PTPN14, E-cadherin and ZO-1 at cell:cell contacts (Figure 4C, bottom panel).  
Z-stack images show that PTPN14 overlaps with the AJ protein, E-cadherin, in both the early 
and late stages of junctional development (Figure 4D, 12-36 hours) and with the TJ protein, ZO-
1, in the late stages of junctional development (Figure 4D, 24 hour and 36 hour). 
Immunoprecipitation of PTPN14-containing complexes during junction development found that 
PTPN14 physically associates with E-cadherin in the early and late stages of junctional 
development (0, 12, 36 hours) and ZO-1 during the late stages of junctional development (36 
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Figure 4. PTPN14 localizes to cell contacts during epithelial junction development. 
Localization of endogenous E-cadherin and PTPN14 in the primordial lumen of wild-type Caco-
2BBE cells. E-cadherin and PTPN14 localize to the periphery and apical (inner) surface at the 2-
cell stage with an increase in E-cadherin at the edge of the primordial lumen. White arrows point 
to E-cadherin clusters at the edges of the primordial lumen. Scale bars, 5µm. B) Localization of 
endogenous E-cadherin, PTPN14 and ZO-1 in mature wild-type 3D cysts. E-cadherin localizes 
basal surface and at cell:cell contacts while ZO-1 localizes to the apical (inner) surface of the 
cyst. PTPN14 overlaps with both E-cadherin and ZO-1. Scale bars, 50µm. C) 
Immunofluorescence of calcium starved (nascent junctions) and calcium treated cells (mature AJ 
and TJ) with antibodies against the TJ protein ZO-1, PTPN14 and E-cadherin.  PTPN14 localizes 
to the cell membrane during both early and late junctional development. Scale bars, 20µm. D) 
Confocal z-stack images during junctional development (Ca2+ treatment) showing that PTPN14 
overlaps with E-cadherin in the early stages of junctional development (12 and 24 hour) and E) 
with both E-cadherin and ZO-1 in the late stages of junctional development (24 and 36 hour). 
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Figure 5. PTPN14 associates with the AJ and TJ proteins during junction development.  
Immunoprecipitation of PTPN14 containing protein complexes at different stages of junctional 
development as indicated by increasing time of calcium treatment.  PTPN14 containing 
complexes were probed with antibodies against Z0-1, E-cadherin and PTPN14 to show that 

























	   32	  
PTPN14 is necessary for lumen formation and junction organization 
 
Development of epithelial cell junctions is directly tied to formation of apicobasal 
polarity and lumen formation84,94. The observation that PTPN14 localizes with both AJ and TJ 
proteins during junctional development led us to question whether PTPN14 regulates junction 
organization. To this end, we infected Caco-2 cells with a scrambled shRNA and two 
independent shRNA constructs targeting PTPN14 (Figure 6A). qRT-PCR analysis and direct 
Western blot show a marked decrease in PTPN14 RNA and protein with no change in AJ protein 
levels (Figure 6A). To determine if PTPN14 has a role in lumen development, we performed a 
3D culture lumen formation assay on scramble control and PTPN14-shRNA cells. In control 
cells ZO-1 marks TJ at the apical surface, actin concentrates at the apical domain and at cell 
contacts, and β-catenin, a known PTPN14 substrate 67 and a component of the AJ, is distributed 
to the basolateral portion of the lumen (Figure 6B, top panel). Surprisingly, PTPN14-shRNA 
cells grown in 3D failed to form lumens, lacked ZO-1 and β-catenin organization and had a 
disorganized actin cytoskeleton (Figure 6B) indicating that PTPN14 is necessary for lumen 
formation and organization of cell contacts during epithelial morphogenesis. In 2D culture, 
PTPN14-shRNA cells showed diminished levels of PTPN14, lacked organization of ZO-1 and 
had reduced localization of E-cadherin at the membrane compared to control cells (Figure 6C) 
suggesting a role for PTPN14 during cell junction development.  
 
PTPN14 depletion disrupts formation of functional epithelial cell junctions 
 TJs regulate cell polarity by serving as a fence that restricts apical and basolateral 
membrane proteins to their respective cellular compartments24-26. The observation that PTPN14-
shRNA cells do not form polarized epithelial cysts suggests that these cells have altered cell  
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Figure 6. PTPN14 is necessary for lumen formation and junction organization A) Direct 
Western analysis and quantitative qRT-PCR using two independent probes demonstrates 
knockdown of PTPN14 in two separate shRNA-mediated knockdown constructs of PTPN14 
(PTPN14-shRNA) in Caco-2BBE cells but no alteration of overall TJ or AJ protein levels. B) 
PTPN14-shRNA cells exhibit a no lumen phenotype, with mislocalization of ZO-1 and E-
cadherin, in a 3D cyst formation culture assay as compared to control (scr-shRNA) cells. Scale 
bars, 20µm. C) Immunofluorescence of scramble (scr-shRNA) and PTPN14-shRNA expressing 
cells using antibodies against ZO-1, PTPN14 and E-cadherin demonstrating decreased PTPN14 
alters TJ and AJ protein localization at cell:cell contacts. Scale bars, 20µm.  
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contacts. To determine if PTPN14-shRNA cells form functional TJs we first quantitated the 
distribution of ZO-1 in PTPN14-shRNA cells compared to control cells. Control cells have ZO-1 
staining at distinct cell contacts compared to the diffuse and mislocalized membrane staining 
observed in PTPN14-shRNA cells (Figure 7A). Intensity profile analysis revealed a lack of 
defined peak in intensity at cell-cell contacts in PTPN14-shRNA cells (Figure 7B). We next 
measured trans-epithelial resistance (TER) over time following a calcium switch (as detailed in 
Figure 4C)84 to determine if the altered ZO-1 cell junction localization in PTPN14-shRNA cells 
corresponded with the loss of TJ function. Control cells showed an increase in TER with 
increased time of calcium treatment, whereas cells expressing decreased levels of PTPN14 
displayed disrupted TER formation (Figure 7C). This finding indicates that PTPN14 activity is 
crucial for epithelial TJ function.  
We previously demonstrated that formation of functional TJs in epithelial cells is 
dependent upon both AJ proteins and cell polarity proteins 84. To determine if decreased levels of 
PTPN14 altered AJ formation we first examined the localization of β-catenin, an AJ protein and 
PTPN14 substrate67  in control and PTPN14-shRNA Caco cells. This analysis revealed a diffuse 
staining pattern at the membrane, similar to what we observed in 3D cyst cultures (compare 
Figure 6B & Fig. 7D). As we also observed altered actin organization in PTPN14-shRNA cells 
in 3D cyst cultures, we next sought to determine if actin organization was altered in monolayer 
cultures. We stained control and PTPN14 depleted cells with Phalloidin to label the actin 
cytoskeleton. PTPN14-shRNA cells displayed evidence of disrupted actin organization at cell 
contacts (Figure 7D), suggesting that the actin cytoskeleton is unable to sense and respond to cell 
contacts in these cells. To determine if the altered actin organization observed in PTPN14-
shRNA cells resulted from alterations in AJ function, we assessed the capacity of cells to form  
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Figure 7. PTPN14 depletion disrupts formation of functional epithelial cell junctions.  
A) Intensity profile staining of ZO-1 in scr- and PTPN14-shRNA expressing Caco-2BBE cells. 
Scale bars, 20µm. B) Quantitation of ZO-1 staining intensity plotted across the cell membrane. 
Scr-shRNA cells display peaks of ZO-1 intensity while ZO-1 is mislocalized and displays a 
diffuse staining pattern in PTPN14-shRNA cells. C) Trans-epithelial resistance (TER) of 
confluent scr-shRNA or PTPN14-shRNA expressing Caco-2BBE cells revealed decreased TJ 
function in cells depleted of PTPN14. Values equal mean (n=2) +/- SD. D) Phalloidin staining 
revealed altered actin organization in PTPN14 knockdown cells. β-catenin localizes to the 
membrane in PTPN14-shRNA cells. Scale bars, 20µm. E) PTPN14-shRNA cells fail to form 
large cell clumps, indicative of stabilized AJ, in hanging drop assays.  
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functional AJs in a hanging drop assay84,130. Control cells showed a step-wise increase in 3-6 cell 
and 7+ cell clumps with increasing time demonstrating their ability to initiate and stabilize 
cadherin-mediated adhesion (Figure 7E). Conversely, PTPN14-shRNA cells were able to form 3-
6 cell clumps like control cells, but were unable to form larger clumps suggesting that although 
these cells are able to initiate cadherin contacts, they are unable to stabilize AJ contacts. The lack 
of stabilized AJs, together with the alterations in actin organization at cell contacts, indicates that 
PTPN14 function is necessary for AJ stabilization during epithelial morphogenesis.  
 
PTPN14 regulates β-catenin-Y654 phosphorylation 
Previous reports identified β-catenin as a substrate of PTPN14 in polarized kidney 
epithelial cells67.  However, the tyrosine residue at which PTPTN14 dephosphorylates β-catenin 
remained unknown67. β-catenin contains at least three potential sites for PTPN14-mediated de-
phosphorylation: tyrosine residues 142, 489 and 654. Phosphorylation at these tyrosine residues 
controls the interaction of β-catenin with other AJ proteins, thereby aiding in regulation of cell 
adhesion. Phosphorylation of β-catenin-Y142 by the FER and Fyn kinases reduces the binding of 
β-catenin with the AJ protein, α-catenin, and facilitates the interaction of β-catenin with the 
human proto-oncogene product, BCL-9169-172. In vitro kinase assays demonstrated that β-catenin-
Y489 is phosphorylated by Abl kinase, eliciting dissociation of β-catenin from N-cadherin and 
localization of phospho-β-catenin-Y489 to the nucleus where it is able to promote transcriptional 
activation173. Additionally, pp60c-src kinase phosphorylates β-catenin at Y654, which regulates 
AJ-mediated adhesion174. Our observations that depletion of PTPN14 disrupts AJ formation led 
us to assess these candidate tyrosine residues of β-catenin to determine if PTPN14 regulates a 
specific tyrosine phosphorylation site. Confluent monolayers of control shRNA and PTPN14-
shRNA Caco-2 cells were collected and probed with phospho-specific antibodies towards β-
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catenin-Y142, -Y489 or -Y654. Phospho-β-catenin-Y489 was not detected in either control or 
PTPN14 depleted cells (Figure 8A); this finding is not unexpected given the lack of N-cadherin 
expression in these cells (data not shown). Additionally, we observed no change in phospho-β-
catenin-Y142 levels between the two cell lines (Figure 8A). An increase in phospho-β-catenin-
Y654 was observed in PTPN14-shRNA cells compared to scr-shRNA cells (Figure 8A) 
suggesting PTPN14 can dephosphorylate β-catenin at Y654. Densitometry analysis of four 
independent confluent cell lysates showed a near two-fold increase in tyrosine phosphorylation at 
β-catenin-Y654 in PTPN14-shRNA cells (Figure 8B). Similarly, indirect immunofluorescence 
staining of confluent cells revealed increased levels of phospho-β-catenin-Y654 staining at sites 
of cell contact in PTPN14-depleted cells, but no change in levels of pY142 (Figure 8C). Intensity 
profiles across an approximate 400µm cell layer (white line in Figure 8C) of both cell types 
indicated the intensity of phospho-β-catenin-Y142 staining was not increased in PTPN14 
depleted cells compared to control cells similar to our observation by direct Western analysis 
(Figure 8A). Intensity profiles for phospho-β-catenin-Y654 in both cell types showed an increase 
in staining intensity across the monolayer of PTPN14-shRNA cells (Figure 8C) suggesting 
PTPN14 regulates β-catenin-Y654 phosphorylation near sites of cell contact. 
 
PTPN14 regulates membrane mobility of E-cadherin at cell contacts 
 Src-mediated β-catenin-Y654 phosphorylation disrupts E-cadherin-dependent cell 
adhesion161,174. We observed that cells depleted of PTPN14 have altered AJ function and 
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Figure 8. PTPN14 regulates β-catenin-Y654 phosphorylation. A) Direct Western analysis of 
indicated Caco-2BBE cells showing an increase of β-catenin Y654 phosphorylation in two 
separate PTPN14-shRNA expressing cells as compared to scramble-shRNA control cells.  
PTPN14 knockdown did not alter levels of β-catenin Y142 and Y489 phosphorylation. B) 
Densitometry comparison of β-catenin pY654 and pY142 between scramble control (scr-shRNA) 
and two PTPN14-shRNA expressing cells showing a significant increase in β-catenin Y654 
phosphorylation in cells that have decreased PTPN14. Values equal mean (n=4) +/- SD (*=p 
<0.05). Asterisks denote a significant difference between the experimental and control values, as 
assessed using the T-test p < 0.05. C) Immunofluorescence quantification of phospho-β-catenin-
Y142 (top panels) or phospho-β-catenin-Y654 (bottom panels) by using the brightness intensities 
of each pixel. PTPN14 knockdown cells display an increase in phospho-β-catenin-Y654 (red line, 
bottom panel) as plotted on the graph in the right panel. Scale bars, 20µm.  
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E-cadherin and β-catenin membrane mobility have a role in regulating cadherin mediated 
adhesion175. This led us to examine the membrane mobility of E-cadherin in PTPN14-shRNA 
Caco-2 cells. In order to address characteristics of E-cadherin mobility, we performed live-cell 
imaging studies to look at E-cadherin at cell:cell contacts. E-cadherin was visualized in Caco-2 
cells by stable infection with lentivirus expressing GFP-tagged E-cadherin while simultaneously 
expressing shRNA targeting endogenous E-cadherin to eliminate any effects of protein 
overexpression176. 
In scramble control Caco-2 cells GFP-E-cadherin primarily moves laterally along cell 
contacts with some apicobasal movement in the cell contacts as previously described176 (Figure 
9A and B). By contrast, PTPN14-shRNA cells display a large increase in GFP-E-cadherin 
movement on and off the membrane at cell contacts (Figure 9A and B). Although the velocity of 
lateral (y plane) GFP-E-cadherin movement was similar between PTPN14-shRNA and control 
cells (Figure 9B), we observed significant increases in apicobasal (z plane) and movement on 
and off the membrane (x plane) in cells with decreased PTPN14 (Figure 9B).  These results 
support a role for PTPN14 in regulating E-cadherin mobility at cell contacts. Next, we used 
Fluoresence Recovery After Photobleaching (FRAP) to examine the dynamics and turnover of E-
cadherin at the cell membrane. In control cells, GFP-E-cadherin half-life recovery after 
photobleaching averaged 60 seconds with the highest percentage of recovery at 68%. Conversely, 
cells with decreased PTPN14 had an average E-cadherin-GFP half-life of 17 seconds and the 
highest percentage of recovery at 100% (Figure 9C-E). We expressed a full-length shRNA-
resistant PTPN14 construct in PTPN14-shRNA cells (Figure 10) and examined E-cadherin 
mobility by live-cell imaging. We observed a decrease in apicobasal movement and movement 
on and off the membrane with no change in lateral movement (Figure 9F). Quantitative analysis  
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Figure 9. PTPN14 regulates membrane mobility of E-cadherin at cell contacts. A) Live-cell 
imaging of GFP-E-cadherin in scr- and PTPN14-shRNA Caco-2BBE cells shows an overall 
increased scattered movement of E-cadherin in PTPN14-depleted cells (top panel). Single 
cell:cell contact analysis confirms increased movement on and off the membrane in cells with 
decreased PTPN14 (bottom panel). B) Quantitative analysis of E-cadherin movement in 
confluent scr- and PTPN14-shRNA cells shows a change in movement on and off the cell 
membrane (x plane). Values equal mean +/- SD (*=p <0.05).  C) FRAP analysis of scr- (top) and 
PTPN14-shRNA (bottom) cells shows an increase in E-cadherin-GFP recovery following photo-
bleaching in PTPN14-shRNA cells compared to control (scr-shRNA) cells indicating an increase 
in E-cadherin movement at cell:cell contacts. Arrows demarcate photo-bleached spots. D) 
Kymograph chart of FRAP data representing the region of interest (ROI) shown in (C). E) 
Plotted parameters for recovery kinetics with an average of 20 ROIs for each cell type 
demonstrating a significant increase in recovery time in PTPN14-depleted cells.  F) Live-cell 
imaging of E-cadherin-GFP in PTPN14-shRNA cells expressing sh-RNA resistant full-length 
PTPN14. Increased movement of E-cadherin-GFP observed in PTPN14-shRNA cells is blocked 
by expression of PTPN14 (top panel). Single cell:cell contact analysis in full-length re-
expression cells demonstrates decreased E-cadherin mobility in PTPN14-shRNA cells re-
expressing PTPN14 (bottom panel).  G) Quantitative comparison of E-cadherin movement 
between cells with depleted PTPN14 (PTPN14-shRNA B, light bars) and re-expression of full-
length PTPN14 (dark bars) demonstrate that re-expression of PTPN14 reduces E-cadherin 















	   42	  
 
Figure 10. Re-expression of full-length PTPN14. Direct Western blot analysis confirming 
endogenous levels of PTPN14 in control cells, decreased PTPN14 through shRNA interference 
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determined that re-expression of full-length PTPN14 reduces the increased movement of E-
cadherin on and off the membrane observed in cells with decreased PTPN14 (Figure 9G) 
indicating that PTPN14 functions to confine E-cadherin mobility at cell contacts.  
 
PTPN14 stabilizes E-cadherin mobility by opposing Src kinase activity at β-catenin-Y654. 
 Our observations that Caco-2 cells depleted of PTPN14 have increased phospho- β-
catenin-Y654 and increased E-cadherin movement on and off the membrane led us to ask if 
PTPN14 phosphatase activity was necessary for regulating E-cadherin membrane movement. To 
directly determine if regulation of E-cadherin mobility at cell contacts is dependent upon 
PTPN14 phosphatase activity, we performed live-cell imaging experiments in PTPN14 shRNA 
Caco-2 cells expressing shRNA-resistant phosphatase dead PTPN14 mutant (PTPN14C1121S)71 
and GFP-E-cadherin. Expression of PTPN14C1121S had no effect on E-cadherin movement on and 
off the membrane (Figure 11A, left panel). Also, the velocity of E-cadherin movement on and off 
the membrane does not change between decreased PTPN14 (PTPN14-shRNA B, left panel) and 
over expression of PTPN14C1121S in Caco-2 cells with decreased PTPN14 (Figure 11B, middle 
panel). Through this, we determined that the control of E-cadherin mobility at the membrane is a 
phosphatase-dependent role of PTPN14.  
From our observations that PTPN14 phosphatase activity is required to regulate E-
cadherin mobility, we then investigated if PTPN14 opposed Src kinase activity, which is known 
to phosphorylate β-catenin-Y654 at cell contacts161. PTPN14-shRNA Caco-2 cells were pre-
treated with 150nM of Dasatinib, a small molecule inhibitor of the Src family kinases (SFK)177-
179 and GFP-E-cadherin movement was observed by live-cell imaging (Figure 12). Dasatinib 
treatment blocked increased movement of E-cadherin on and off the membrane in cells with 
decreased PTPN14 (Figure 11A, right panel) and quantitative evaluation of E-cadherin mobility 
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revealed E-cadherin movement on and off the membrane was decreased in a similar fashion to 
re-expression of full-length PTPN14 (Figure 11B, right panel). These data indicate that PTPN14 
phosphatase activity opposes Src kinase activity at cell contacts.   
We next asked if the increased movement of E-cadherin observed in cells with decreased 
levels of PTPN14 could be rescued by preventing phosphorylation of β-catenin-Y654. Whereas 
over-expression of β-cateninWT did not alter the increased movement of E-cadherin at the 
membrane in cells with depleted levels of PTPN14 (Figure 11C), cells expressing the non-
phosphorylatable β-cateninY654F mutant showed a significant decrease in overall E-cadherin 
movement (Figure 11E), reaching levels similar to those in control cells (Figure 11F). These 
results indicate that PTPN14-mediated dephosphorylation of β-catenin-Y654 stabilizes E-
cadherin mobility at cell contacts. 
 
PTPN14 activity is necessary for E-cadherin-mediated lumen formation  
 Caco-2 lumen formation derives from a single cell that polarizes centrosomes under an 
actin-rich cap prior to the first cell division.  Although the role of E-cadherin-mediated adhesion 
during early lumen formation is not understood94,180, our results  (Figure 4A and B) suggest that 
E-cadherin localization is highly regulated at this stage of lumen morphogenesis. To determine 
how PTPN14-mediated regulation of E-cadherin affects early lumen formation, we first 
examined E-cadherin localization immediately following the first cell division in Caco-2 3D 
cultures. In control cells E-cadherin localized around the outside of both cells and to an E- 
cadherin bridge that connects the newly divided cells (Figure 11G, top panel). Actin concentrates 
at this E-cadherin bridge. In PTPN14-shRNA cells, the E-cadherin bridge fails to form (80%) 
and actin does not organize to the cell:cell contact which will serve as the site for initial lumen 
formation (Figure 11G, middle panel). Inhibition of Src kinase activity rescues formation of the 
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Figure 11. PTPN14 stabilizes E-cadherin mobility by opposing Src kinase activity at β-
catenin-Y654. A) Live-cell imaging of E-cadherin-GFP in PTPN14-shRNA Caco-2BBE cells 
expressing a phosphatase -dead mutant, PTPN14C1121S, and cells treated with 150nM of the Src 
inhibitor, Dasatinib. PTPN14C1121S does not alter the increased mobility of E-cadherin observed 
in PTPN14-depleted cells; by contrast, treatment with Dasatinib decreases mobility of E-
cadherin at the membrane in PTPN14-shRNA cells (top panel). Bottom panel represents a single 
cell:cell contact.  B) Quantification of E-cadherin movement at cell:cell contacts in full-length 
re-expression and Dasatinib treatment, but not phosphatase dead PTPN14, significantly 
decreases E-cadherin movement on and off the membrane of cells depleted of PTPN14. Values 
equal mean +/- SD (*=p <0.05).  C) Live-cell imaging of E-cadherin-GFP in scr- and PTPN14-
shRNA cells overexpressing wild-type β-catenin (scr-shRNA + β-cateninWT and PTPN14-
shRNA + β-cateninWT, respectively). Expression of wild-type β-cateninWT does not alter the 
increased mobility of E-cadherin observed in PTPN14-shRNA cells (top panel). Bottom panel is 
a single cell:cell contact view of each cell type.  D) Quantitative analysis of E-cadherin 
movement in cells from (C). Values equal mean +/- SD (**=p <0.005).  E) Live-cell imaging of 
E-cadherin-GFP in scr- and PTPN14-shRNA cells overexpressing non-phosphorylatable mutant 
of β-catenin at tyrosine 654 (β-cateninY654F). Expression of β-cateninY654F in PTPN14-shRNA 
cells decreases overall E-cadherin movement (top panel). Single cell:cell contact analysis also 
reveals a decrease in E-cadherin movement at the cell membrane (bottom panel).  F) 
Quantitation of E-cadherin movement in cells from (E).  Expression of β-cateninY654F rescues the 
increased movement of E-cadherin in cells with decreased PTPN14.  G) Immunofluorescence 
staining of Caco-2BBE 3D cultures  with an antibody against E-cadherin and Phalloidin to label 
actin at the 2-cell stage. Cells with decreased PTPN14 expression exhibit disrupted actin and E-
cadherin localization at the 2-cell stage. Treatment with 150nM Dasatinib rescues the 
localization of E-cadherin and actin demonstrating that Src inhibition can rescue the effects of 
decreased PTPN14 during early lumen formation. Bars, 10µm for top and bottom panels; 5µm 
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Figure 12. β-catenin protein expression and measurement of Src activity. Confluent Caco-2 
cells were treated with the indicated concentrations of Dasatinib two times per day for two days 
and collected for direct Western.  Lysates were probed with antibodies detecting total Src (tSrc) 
or phosphorylated Src (Y416) to show that 150 and 200 nM concentrations of Dasatinib 
decreased Src activity in Caco cells.  B) scr-shRNA or PTPN14-shRNA Caco cells were infected 
with either Myc tagged wild-type β-catenin (β-cateninWT-myc) or a non-phosphorylatable β-
catenin-Y654F mutant (β-cateninY654F-myc).  Direct Westerns of the indicated lysates were 
probed with antibodies recognizing the Myc tag to show expression of the indicated constructs or 
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Figure 13.  Quantitation of E-cadherin bridge during early lumen formation.  The presence 
of an E-cadherin bridge in early 2-cell cysts was counted in scr-shRNA, scr-shRNA + 150nM 
Dasatinib, PTPN14-shRNA and PTPN14-shRNA + 150nM Dasatinib.  Primordial lumen 
formation is decreased by 80% in cells with decreased PTPN14 and can be partially rescued by 
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E-cadherin bridge and actin localization at the initial cell contact (Figure 11G, bottom panel; 
Figure 13). These data demonstrate that PTPN14 opposes Src kinase activity on β-catenin at the 
two-cell stage of lumen formation to establish an E-cadherin bridge in the early stages of lumen 
formation. 
 To understand if control of E-cadherin mobility by PTPN14 has a functional role after the 
two-cell stage, we re-expressed shRNA-resistant PTPN14 in PTPN14-shRNA cells and 
examined 3D lumen formation. In agreement with our previous observations, (Figure 6B, bottom 
panel), cells depleted of PTPN14 do not form a lumen in 3D. We also observed mislocalization 
of  ZO-1 and β-catenin, as well as actin disorganization. Interestingly, we also noted a complete 
loss of the apical protein, Ezrin, in 3D cysts that lack PTPN14 (Figure 14A, top panel). When 
full-length PTPN14 is expressed in PTPN14-shRNA cells, a lumen forms in Caco-2 cells (Figure 
14A). Ezrin concentrates to the apical domain and actin is concentrated at the surface of the 
lumen (Figure 14A, bottom panel). This indicates that PTPN14 re-expression is sufficient to 
promote the formation of a single lumen in Caco-2 cells. To determine if PTPN14 establishes 
this lumen by regulation of phospho-β-catenin-Y654, we expressed β-cateninY654F in either 
control shRNA cells or cells with decreased PTPN14 and witnessed a similar outcome as what is 
observed when we express full-length PTPN14.  These cells localize Ezrin to the apical domain 
and actin is organized around the primordial lumen (Figure 14B, bottom panel). We also 
observed polarized cell division occurring parallel to the apical surface, which is indicative of 
establishment of apicobasal polarity in the cyst (Figure 14B, bottom panel, white arrow). These 
data establish a functional role for PTPN14 in 3D cyst development in intestinal epithelial cells 
through the regulation of β-catenin-Y654. 
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Figure 14. PTPN14 activity is necessary for E-cadherin-mediated lumen formation 
A) PTPN14-shRNA cells have a no lumen phenotype and lose the apical marker, Ezrin, in 
mature 3D cysts and exhibit actin disorganization (top panel). Expression of shRNA- resistant 
full-length PTPN14 rescues actin and Ezrin localization in 3D cysts (bottom panel) indicating 
that PTPN14 is required for apical-basal polarity in Caco-2BBE cells. Scale bars, 20µm. B) 
Overexpression of a non-phosphorylatable mutant of β-catenin at Y654 (β-cateninY654F) in 
PTPN14 sh-RNA cells promotes Ezrin localization and actin organization towards the early 
lumen (bottom panel). Expression of β-cateninY654F also promotes polarized cell division around 
the early lumen in PTPN14 sh-RNA cells; white arrow demarcates a cell that is correctly 
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Discussion 
 
We present data indicating that the non-receptor tyrosine phosphatase PTPN14 opposes 
Src-mediated disruption of cadherin-mediated cell adhesion thereby resulting in stabilization of 
E-cadherin at cell contacts.  PTPN14-mediated stabilization of E-cadherin at cell contacts 
promotes functional AJ adhesion, TJ adhesion and polarized organization of three dimensional 
cell structures.  We show that endogenous PTPN14 localizes to cell contacts in both 2D and 3D 
cultures of Caco-2BBE epithelial cells, co-localizing with AJ and TJ proteins during specific 
stages of cell junction development.  Moreover, we demonstrate that PTPN14 phosphatase 
activity is necessary for formation of functional AJ, TJ and polarized lumens, and that this 
activity regulates Src-mediated phosphorylation of β-catenin-Y654 thereby stabilizing E-
cadherin at cell contacts. Coupled with our previous work that  demonstrated a requirement for 
AJ proteins to establish apicobasal polarity and functional TJ in epithelial cells 84, our new data 
support the idea that establishment of stable AJs is critical for junction development and 
organization of epithelial cells within the tissue to maintain homeostasis. Although these data 
indicate the importance of the AJ during tissue development, we lack a complete understanding 
of how epithelial cells with established apicobasal polarity and cell junctions respond to altered 
function of PTPN14 (or that of other junctional proteins). Observations reporting mutations or 
changes of expression of PTPN14 in various cancers would suggest that regulation of PTPN14 
levels may be critical for maintenance of epithelial tissues. It does appear, however, that small 
changes in PTPN14 activity can greatly alter epithelial tissues65. The identification of protein(s) 
that regulate PTPN14 should provide insight into the capacity of PTPN14 activity to alter cell 
adhesion and promote or accelerate disease progression.  
Regulation of cadherin-mediated adhesion by growth factors can occur through numerous 
signaling pathways and target different proteins within the AJ.  Phosphorylation of β-catenin by 
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Src regulates E-cadherin adhesion, but it does so in the context of an intact E-cadherin- β-catenin 
protein complex144,172,181. Constitutive, but low-level Src-dependent β-catenin-Y654 
phosphorylation enables the continual lateral movement of E-cadherin at cell contacts; increased 
growth factor-dependent signaling through Src diminishes adhesion159 and allows cells to divide 
and repopulate the tissue.   How PTPN14 activity responds to this varying level of Src activity 
and whether there is a built in feedback loop remains to be seen.  Additionally, how PTPN14-
mediated regulation of β-catenin phosphorylation cooperates with other AJ phosphorylation 
events that alter adhesion, including the phosphorylation of E-cadherin182,183 and p120-
catenin172,174,184,185, will be a critical area to examine.     
Cadherin-mediated adhesion promotes apicobasal polarity and organization of epithelial 
tissues, including tissues containing lumens.  The inability of intestinal cells depleted of PTPN14 
to form a lumen is reminiscent of the no-lumen phenotype observed in Caco cells expressing 
EzrinΔact, a dominant negative form of the apical protein Ezrin94.  In both C. elegans186,187 and 
mouse188 intestine, Ezrin-mediated localization and regulation of membrane pumps is thought to 
direct lumen formation. But how would PTPN14-mediated regulation of E-cadherin alter initial 
lumen formation?  One possibility arises from our observation of E-cadherin localization in 3D 
cultures of 2-cell Caco cysts.  The bridge of E-cadherin observed in control cells suggests that E-
cadherin-mediated adhesion is necessary for lumen establishment.  Perhaps local regulation of E-
cadherin adhesion enables surrounding cells to respond to the increased fluid pressure that results 
from activation of membrane pumps. Indeed, we observe a concentration of actin with this E-
cadherin bridge; this concentration could stabilize the luminal surface in response to increased 
fluidic pressure in the developing lumen.  The discovery and characterization of signals that 
trigger reorganization of E-cadherin from this luminal surface could provide new insight into 
functions of E-cadherin in non-junctional regions of the cell. Indeed, there are likely many 
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additional pathways and molecules that regulate the fine-tuning of cell adhesion and polarity—

















































PTPN14 PROMOTES MESENCHYMAL PHENOTYPES BY 
 DESTABILIZATION OF THE ADHERENS JUNCTION 
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Introduction 
  
More than 90% of cancer related deaths are associated directly to metastasis – the spread 
of tumor cells to distant organs where they establish secondary colonies 189,190. A key part of the 
metastatic cascade is the cellular process called epithelial-mesenchymal transition (EMT), which 
increases the migratory and invasive potential of tumor cells by the loss of cell polarity and cell-
cell adhesion4,191. Accordingly, the loss of these essential epithelial characteristics also 
contributes to chemotherapy resistance because of a hypothesized cancer stem cell (CSC) 
population that retains EMT features192. This remains a significant clinical issue because, after 
treatment, the CSC population in residual tumors aids in chemotherapy resistance and ultimately 
tumor recurrence193. Recently, PTPN14 has been implicated in the direct and indirect regulation 
of signaling pathways, including the TGFβ65and Hippo71-73 pathways, which are known to induce 
EMT in a number of cell lines and tissues.  
TGFβ is a secreted growth factor that interacts with and activates transmembrane 
serine/threonine receptors194. In canonical signaling, the type I receptors phosphorylate and 
activate Smad2/3 that form a complex with Smad4 to shuttle to the nucleus and regulate 
transcription of target genes195. Non-canonical (non-Smad) TGFβ signaling pathways include 
MAPK, Rho-like GTPase and the PI3K/AKT pathways. These non-canonical pathways can have 
cross-talk with canonical TGFβ signaling to elicit diverse responses from the TGFβ receptors196. 
Increased TGFβ signaling was first shown to induce EMT in a cell culture model whereby 
epithelial cells took on morphological changes from a cuboidal to a spindle-cell shape194. This 
morphological change was accompanied by a decrease of the epithelial marker, E-cadherin, and 
an increase in the EMT markers, vimentin and fibronectin194. PTPN14 over-expression is shown 
to induce EMT by increasing canonical TGFβ signaling through Smad4 in MDCK cells65. In 
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vivo studies demonstrate that PTPN14 knockdown in the zebrafish embryo causes loss of TGFβ3 
expression in regions of the developing brain and heart leading to defects in organogenesis65. 
These studies demonstrate potential tumor suppressive and oncogenic functions of PTPN14 via 
the TGFβ pathway, although it is not known whether these are phosphatase-dependent or 
independent functions. 
In addition to TGFβ signaling, PTPN14 directly interacts with and negatively regulates 
Yes-associated protein (YAP), a core component of the Hippo signaling pathway, in a cell 
density-dependent manner 71-73. First discovered in Drosophila the Hippo pathway contains a 
core kinase cascade composed of Mst1/2 (Hippo) and Lats1/2 that dictates the phosphorylation 
state of the transcriptional co-activator, YAP197. Phosphorylated YAP is sequestered in the 
cytoplasm, but nonphosphorylated YAP can enter the nucleus to activate transcription of target 
genes. Multiple studies show that Hippo signaling is not regulated by a set of ligands and 
receptors, but rather by multiple upstream components that feed into the core kinase cascade198, 
most of which have roles in modulating cell polarity and adhesion199,200. The Hippo pathway has 
been implicated in inducing EMT74 and mediating contact inhibition of proliferation201-204. 
Reports highlight a role for the AJ in regulating YAP localization through knockdown of the AJ 
proteins, E-cadherin, α-catenin and β-catenin, which causes an increase in cell proliferation and 
nuclear YAP201,205. Our previous data identifying a role for PTPN14 in the regulation of E-
cadherin membrane mobility (see Chapter 3) may provide a cue for YAP nuclear entry or 
sequestration in the cytoplasm. In most cases, cytoplasmic retention of YAP is mediated through 
the downstream kinase LATS1. It is reported that PTPN14 interacts with LATS1 and the 
upstream Hippo component, Kibra, to regulate the localization of YAP although PTPN14 can 
interact with LATS1 in a Kibra-independent manner206. However, reduced PTPN14 causes 
aberrant acinar formation in mammary epithelial cells (MCF10A), which is rescued by 
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exogenous expression of Kibra, indicating a cross-talk mechanism to control 3D morphogenesis 
206. In this context, the YAP transcriptional targets, CTGF and CYR61, were increased 
suggesting that knockdown of PTPN14 reinforces the oncogenic function of YAP206. Although 
efforts focus on understanding the effects of the Hippo signaling pathway in cell proliferation 
and contact inhibition, its role in EMT remains unclear. A pathway implicated in regulating EMT 
that also has roles in maintaining cell proliferation and differentiation is the Notch signaling 
pathway.  
The Notch signaling pathway is evolutionarily conserved and is linked to cell 
proliferation207, apoptosis208 and differentiation209,210. Notch signaling is carried out by direct 
cell-cell communication where ligands are expressed at the cell membrane to activate receptors 
on a neighboring cell211. Canonical Notch signaling is characterized by a series of proteolytic 
cleavages that prompt the intracellular domain of the Notch receptor to translocate to the nucleus 
and associate with the nuclear effector, CSL (CBF1, Suppressor of Hairless, Lag-1) to activate 
transcription of downstream targets (Reviewed in 212). Aberrant Notch signaling is reported in 
tumorigenesis where it exhibits anti-proliferative and oncogenic functions in a context-dependent 
manner213,214. Importantly, Notch activation results in acquisition of mesenchymal characteristics 
reportedly through the upregulation of the E-cadherin repressors, Snail1215,216 and 
Snail2/Slug217,218. The Notch pathway has also been reported to control cell morphogenesis via 
AJ remodeling in Drosophila ovarian follicles219. Similarly, our observations indicate that 
PTPN14 localizes to the AJ during early junction development and stabilizes the E-cadherin/β-
catenin complex to maintain cell contacts (see chapter 3). Although it is not known whether 
PTPN14 is directly connected to Notch signaling, reports identify the interaction of PTPN14 
with VEGFR3220 and postulate a cross-talk between VEGFR3 and Notch signaling in endothelial 
cells to control proliferation and differentiation221,222. However, it remains unclear whether 
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Notch signals to PTPN14 or PTPN14 regulates a Notch response in cells to orchestrate cellular 
movements and/or maintain cell contacts.  Here we continue our focus on PTPN14 regulation of 
AJ-mediated adhesion and show that decreased PTPN14 activity over time induces a specific 
EMT response through increased Notch signaling and the Snail2/Slug transcription factor.  
 
Results 
Decreased PTPN14 induces mesenchymal features in epithelial cells 
There is significant down regulation of E-cadherin expression in CRC223, which also 
appears to be a critical step in the process of EMT224.  With the observations that PTPN14 is 
crucial for AJ-mediated adhesion and epithelial morphogenesis by regulating E-cadherin 
membrane movement (see chapter 3), we sought to determine if alterations in signaling occur 
over time in cells with depleted PTPN14. To do this, we infected Caco-2 cells with lentivirus 
expressing shRNA constructs targeting PTPN14. Following confirmation of decreased PTPN14 
levels with two independent shRNA constructs, Caco-2 cells with decreased PTPN14 (Figure 
15A) exhibited a change in morphology where the cells took on a more mesenchymal phenotype 
as compared to control cells that display a cobblestone-like morphology (Figure 15B). Since cell 
junctions are important for maintaining cell adhesion, we analyzed cell junction formation in 
confluent cultures. PTPN14 knockdown cells exhibited diminished levels of PTPN14 and E-
cadherin with disrupted ZO-1 membrane staining as compared to control (scr) cells (Figure 16A). 
Since we observe diminished levels of junction proteins and cell migration is dependent on the 
stability of cell:cell contacts, we wanted to determine whether these defects in AJ and TJ proteins 
by knockdown of PTPN14 increases the mobility of cells and their directional motion. In order to 
address this, we performed a scratch assay and captured cell movement by live-cell imaging. By 
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Figure 15. Decreased PTPN14 alters epithelial cell morphology. A) Direct Western analysis 
indicates knockdown of PTPN14 via two separate shRNA-mediated knockdown constructs of 
PTPN14 (PTPN14-shRNA) in Caco-2BBE cells. B) Phase-contrast microscopy image of control 
(scr) and PTPN14 knockdown cells. Decreased PTPN14 causes cells to change from a classic 
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Figure 16. Decreased PTPN14 induces mesenchymal features in epithelial cells.  
A) Localization of ZO-1 (green), PTPN14 (red) and E-cadherin (white) in control (scr) and cells 
exposed to PTPN14 knockdown over an extended amount of time (PTPN14-shRNA). Cells with 
decreased PTPN14 activity over an extended amount of time exhibit mis-localized and reduced 
ZO-1 and E-cadherin, respectively. Scale bars, 20µm. B) Scratch assay tracking individual cell 
movement over time. PTPN14 knockdown cells exhibit loss of collective cell migration and 
travel at double the velocity of control cells. Values equal mean (n=12) +/- SD. C) Growth curve 
assay with indicating that cells with decreased PTPN14 (PTPN14-shRNA) lose contact 
inhibition of proliferation. Values equal mean (n=2) +/- SD 
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tracking individual cells we observed that control cells have directional collective cell movement 
while PTPN14 knockdown cells have loss of this directional movement, increased velocity and 
have a scattered pattern of movement (Figure 16B). These data indicate that PTPN14 knockdown 
cells lack directional collective cell migration and have increased speed of migration (Figure 
16B). We next wanted to determine if the increased mobility of cells and lack of directional cell 
migration globally affects the ability of cells to respond to cell-cell signaling by stopping 
proliferation when they come in contact with one another, a phenomenon known as contact 
inhibition of proliferation (Reviewed in 225). To do this, we performed a growth curve assay 
where cells were plated at the same density and counted every six hours for up to 48 hours post-
confluency. We found that, as compared to control cells that stopped proliferating once the cells 
came in contact with one another, PTPN14 knockdown cells do not undergo contact inhibition 
and thus, cells continue to proliferate (Figure 16C). This loss of contact inhibition of 
proliferation is a common characteristic of tumor cells to regulate tumor growth226. 
 
Cells with diminished PTPN14 activity express markers of EMT 
 
 Our observation of diminished levels of membrane associated E-cadherin in cells 
depleted of PTPN14 suggested we could be altering E-cadherin protein at either a post-
translational or transcriptional level.  We wanted to determine if levels of total E-cadherin 
protein levels is altered in PTPN14-shRNA cells. Direct Westerns show no detectable E-cadherin 
in cells with decreased PTPN14 and the levels of the AJ proteins, α-catenin and p120, and the TJ 
protein, ZO-1, are reduced with decreased PTPN14 while β-catenin levels remain the same 
(Figure 17A). The loss of E-cadherin is a molecular trademark of epithelial to mesenchymal 
transition (EMT), an event that is correlated with more migratory and invasive characteristics in 
tumor cells227,228. There is evidence that E-cadherin transcription is inhibited in EMT by the 
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transcription factors ZEB1229-231, Snail1223,232-235, Snail2/Slug233,236 and Twist223,234. In addition to 
down regulation of epithelial markers, EMT is also distinguished by the presence of markers 
such as N-cadherin and Vimentin231. Together with the increase in cell migration and loss of E-
cadherin, cells with decreased PTPN14 also express the EMT markers N-cadherin, Vimentin and 
the E-cadherin transcriptional repressors ZEB-1 and Snail2/Slug (Figure 17B). The expression of 
N-cadherin at the membrane is similar to what is observed	  during primitive streak ingression in 
normal development when “cadherin switching” occurs237,238 although this can happen in tumor 
cells that have undergone a transition to mesenchymal characteristics239-241. Decreased PTPN14 
causes increased N-cadherin transcription (Figure 17C) and displays membrane localization 
similar to E-cadherin in control cells (Figure 17D). This data indicates that cells with decreased 
PTPN14 exhibit a potential cadherin switch from E-cadherin to N-cadherin at the cell membrane 
potentially playing a role in altered cell adhesion and increased cell migration.  
 
Knockdown of PTPN14 promotes a specific EMT response over time 
 We wanted to determine when E-cadherin expression was reduced in cells with decreased 
PTPN14. Through quantitative RT-PCR, we looked at E-cadherin transcription levels in cells 
that were in culture for an extended amount of time with decreased PTPN14 (middle passage) as 
well as cells that were exposed to PTPN14-shRNA for a short amount of time (early passage).  
We found a step-wise decrease in E-cadherin the longer cells were in culture with decreased 
PTPN14 activity indicating that PTPN14 loss plays a pivotal role in the regulation of E-cadherin 
transcription (Figure 18A). A high percentage of tumor cells that arise from multiple tissues 
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Figure 17. Cells with diminished PTPN14 activity express EMT markers. A) Direct Western 
analysis of AJ and TJ proteins in scr- and PTPN14-shRNA Caco-2 cells. AJ and TJ protein 
levels are decreased in cells with decreased PTPN14. B) Direct Western profile of EMT markers 
showing expression of N-cadherin, Vimentin and the E-cadherin repressors ZEB-1 and 
Snail2/Slug. C) Quantitative RT-PCR using two independent probes demonstrating a significant 
increase in N-cadherin transcription in PTPN14-shRNA cells. Values equal mean (n=2) +/- SD 
(***=p<0.001). D) Immunofluorescence staining showing N-cadherin is expressed and localized 
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cadherin repressors, Snail1, Snail2/Slug, ZEB-1 and Twist (Reviewed in 242).  Most notably, the 
E-cadherin repressor Snail2/Slug, serves as a potential predictive biomarker for metastasis and 
poor prognosis in CRC243. Along with a step-wise decrease in E-cadherin we see a step-wise 
increase in Slug transcription, suggesting that PTPN14 directly or indirectly regulates the 
transcription of Slug to induce EMT characteristics (Figure 18B). We examined E-cadherin 
transcription in cells with longer exposure to decreased PTPN14 (late passage) and found that 
there was no detectable E-cadherin transcription while knockdown of PTPN14 remained the 
same (Figures 18C and D). This suggests that prolonged decreased PTPN14 causes an EMT 
response over time specifically through the Snail2/Slug transcription factor.  
 
Decreased PTPN14 activity triggers Notch signaling  
 To determine if induction of EMT characteristics in PTPN14 knockdown cells were due 
to alterations of pathways that are regulated by PTPN14, we examined the targets of the TGFβ 
and Hippo pathways. PTPN14 is implicated in controlling TGFβ signaling through increased 
nuclear translocation of the downstream signaling effector Smad4 in canine MDCK cells65. In 
control cells, Smad4 remained predominantly cytoplasmic (Figure 19A, top panel). In addition, 
PTPN14 knockdown cells also had cytoplasmic Smad4 (Figure 19A, bottom panel), indicating 
that these cells do not have increased TGFβ signaling through Smad4. In addition, in mammary 
epithelial cells (MCF10A), PTPN14 negatively regulates the oncogenic function of the 
downstream pathway component, Yes-Associated protein (YAP)202. When Hippo signaling is 
deregulated, YAP enters the nucleus and subsequently triggers activation of target genes  
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Figure 18. Knockdown of PTPN14 promotes a specific EMT response over time.  
A) Quantitative RT-PCR using two independent probes shows a significance step-wise decrease 
in E-cadherin transcription in PTPN14-shRNA early and middle passage cells. Values equal 
mean (n=3) +/- SD. B) Comparison of Snail and Slug transcription by qRT-PCR in PTPN14 
knockdown cells. Slug transcription exhibits a step-wise increase over time with exposure to 
decreased PTPN14 activity while Snail transcription does not change. Values equal mean (n=2) 
+/- SD (*=p<0.05). C) E-cadherin transcription by qRT-PCR using two independent probes in 
PTPN14 knockdown cells. A late passage of E-cadherin shows virtually no transcription 
suggesting that E-cadherin is being transcriptionally repressed over time while PTPN14 
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Figure 19. EMT in cells with decreased PTPN14 is independent of TGFβ  and Hippo 
signaling. A) Staining with total YAP antibody reveals that YAP is cytoplasmic in both control 
(scr) and PTPN14 knockdown confluent cells. These data indicate no increased nuclear YAP, 
therefore proposing a YAP-independent function of PTPN14 in Caco-2 cells. Scale bars, 10µm. 
B) Smad4 staining is cytoplasmic in both control (scr) and PTPN14-shRNA cells, indicating no 
increased translocalization of Smad4 to the nucleus and subsequent increase in TGFβ signaling 
in PTPN14 knockdown cells. Scale bars, 10µm. C) Quantitative RT-PCR probing for YAP 
targets, AREG, BIRC3 and CTGF1 in control and  PTPN14 knockdown early, middle and late 
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(Reviewed in 244). YAP localization did not change between control and PTPN14 knockdown 
cells (Figure 19B) and the YAP transcriptional targets; AREG, BIRC3 and CTGF1 did not 
appear to have any distinct changes to correlate with the EMT phenotype observed in cells with 
decreased PTPN14 (Figure 19C). These data suggest a YAP-independent function of PTPN14 in 
intestinal epithelial cells. Given that there is no change in pathways that are regulated by 
PTPN14, we utilized a non-biased approach and performed reverse phase protein array (RPPA) 
analysis on control (scr), early (93C), middle (93B) and late (93A) depleted PTPN14 cells 
(Figure 20). We confirmed our IF findings by observing no change in TGFβ signaling by Smad1, 
3 and 4. Similar to what we saw by IF, we saw an increase in total YAP, but with an increase in 
phospho-YAP-S127 that blocks YAP activation202. Lastly, we uncovered a step-wise increase in 
Notch1 over time when cells are exposed to lower levels of PTPN14 activity. 
 Canonical Notch signaling occurs when there is an extracellular interaction of a Notch 
transmembrane ligand with a Notch transmembrane receptor; this interaction initiates proteolytic 
cleavage of the Notch receptor and release of its intracellular domain (ICD) (Reviewed in 212). 
Notch ICD translocates to the nucleus and interacts with CSL (CBF1/Suppressor of 
Hairless/LAG-1) to initiate the transcription of Notch target genes245.  We probed confluent 
whole cell lysates with antibodies to detect Notch1 and Notch2 and observed a step-wise 
increase of both the Notch 1 and 2 ICD corresponding with an increase in the time the cells have 
been depleted of PTPN14 (Figure 21). The decreased adhesion of PTPN14 late depleted cells 
due to cadherin switching would likely prevent Notch signaling from increasing since the Notch 
signaling cascade is dependent on cell membrane bound receptors and ligand interactions. These 
data suggest a potential regulation of Notch signaling in cells with decreased PTPN14 activity. 
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Figure 20. Reverse Phase Protein Array (RPPA) for Caco-2 cells of varying lengths of time 
with decreased PTPN14 activity. Duplicate control (scr - right), early (93C), middle (93B) and 
late (93A - left) depleted cells were stained for 285 unique antibodies and were analyzed on 
Array-Pro then by supercurve Rx64 3.1.1. Samples were probed with the antibodies using a CSA 
amplification approach and visualized by DAB colorimetric reaction. The heatmap was 
generated in Cluster 3.0 as a hierarchial cluster using Pearson Correlation and shows overall 
patterns of protein levels. A green signal indicates a decrease in protein while a red signal 
indicates an increase in protein level. The RPPA Core Facility at MD Anderson completed all 
analyses. * indicates Smad protein; ** marks YAP protein and *** designates Notch protein 
levels in cells with depletion of PTPN14. A step-wise increase of Notch was observed in cells 
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Figure 21. Decreased PTPN14 activity triggers an increase in Notch. Direct Western analysis 
indicating an increase in Notch1 and 2 in PTPN14 knockdown cells. The increase in Notch1/2 is 
seen in early and middle passages of cells with reduced PTPN14 activity; however, Notch1 
decreases when cells undergo an EMT-like phenotype, suggesting that Notch signaling may be 
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Discussion 
In recent years, our understanding of EMT has greatly increased yet many questions 
remain on the molecular mechanisms that govern the changes that occur to eventually cause 
epithelial tumors to acquire mesenchymal characteristics and metastasize. These data 
demonstrate that over an extended amount of time, decreased activity of the tyrosine phosphatase, 
PTPN14, causes an EMT response in cultured epithelial cells. Our previous findings illustrate a 
role for PTPN14 in the stabilization of AJ-mediated adhesion through maintenance of β-catenin-
Y654 phosphorylation (See Chapter 3). It is well known that cell:cell adhesion and polarity 
orchestrate a highly regulated EMT process in normal developmental4,246. However, cancer cells 
hijack this biological process to acquire more migratory and invasive characteristics247, making 
the pathological process of tumor EMT quite difficult to delineate. By examining cells with 
varying lengths of time with decreased PTPN14 activity, we identified a step-wise decrease in E-
cadherin transcription coupled with increase of the Snail2/Slug transcription factor while 
decreased PTPN14 transcript levels remained the same. This highlights a potential tumor 
suppressor function of PTPN14 that primes cells to undergo EMT. However, whether or not 
additional alterations occur to cause this transition is yet to be determined. Since PTPN14 
overexpression is shown to induce EMT through regulation of TGFβ signaling in MDCK cells65, 
we saw this as a candidate pathway, however we did not observe any increase in TGFβ signaling 
by Smad4 or Smad3 (data not shown) translocalization to the nucleus. Also, PTPN14 is 
implicated in Hippo signaling and subsequent YAP-dependent migration in mammary epithelial 
cells72, but we did not observe any nuclear YAP in cells that underwent EMT. This was an 
interesting find since cells with decreased PTPN14 exhibit loss of contact inhibition of 
proliferation and studies suggest that proliferating cells normally exhibit nuclear YAP202. From 
this, our data suggests that PTPN14 may have a cell-specific effect on signaling in intestinal 
	   72	  
epithelial cells independent of TGFβ and Hippo signaling. One proposed mechanism from our 
work is that PTPN14 may be regulating Notch signaling.  
Notch signaling is an evolutionarily conserved pathway248 that mediates cell survival249 
and cell-fate determination during development209. We see a step-wise increase over time of 
Notch1 and Notch2 in cells with decreased PTPN14. Reports identify that Snail2/Slug is a direct 
target of Notch in cardiac endothelial cells to induce EMT217. The step-wise increase we see of 
Notch1 and 2 coupled with the increase in Snail2/Slug transcription begs the question of whether 
PTPN14 alone is responsible for the upregulation of Notch signaling to elicit a conversion of 
epithelial cells to acquire mesenchymal characteristics. These questions remain unanswered at 
this time, however the identification that decreased PTPN14 activity as a key factor in tumor 




































DEFINING THE FUNCTION OF THE NF2 TUMOR SUPPRESSOR PROTEIN, MERLIN, 
IN COORDINATING CELL ADHESION AND POLARITY 
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Introduction  
Development of epithelial cell junctions involves a process where an immature junction 
containing both the AJ and TJ proteins transitions into distinct polarized AJ and TJ structures 
with the final placement of the TJ just apical of the AJ181,250,251. Work has revealed that the 
protein product of the Nf2 tumor suppressor gene, Merlin, coordinates cell adhesion and polarity 
of epithelial cells by directly linking the apical polarity protein, Par3, to the AJ protein, α-catenin.  
This physical interaction generating a junctional polarity complex is required in the early stages 
of epithelial junction formation84.  Merlin is a member of the FERM family of proteins 
consisting of a highly structured N-terminal FERM domain and a C-terminal tail connected by a 
flexible linker region.  Unique to Merlin is an unstructured N-terminal region consisting of 17 
amino acids four of which are serines. Deletion of the first 17 amino acids of Merlin blocks 
Merlin tumor suppressor function and recruitment to the actin cytoskeleton98. Recruitment of 
Par3 and aPKC is required for the formation of TJs and the establishment of polarity100,108. Also, 
the N-terminal portion of Merlin is required for association of Par3 with the AJ complex84, which 
may be essential for the initial recruitment of aPKC and TJ proteins. Loss of Merlin causes mis-
localization of aPKC away from the apical cell membrane and inhibits TJ formation84. When 
aPKC kinase activity is blocked, cell polarity is altered and formation of functional TJ is 
blocked100, suggesting that mis-localization of aPKC affects cell membrane organization. This 
indicates that loss of either aPKC or the N-terminal region of Merlin exhibit similar phenotypes 
98. This raises the possibility that aPKC may regulate Merlin-mediated cell polarity and junction 
formation through phosphorylation of the N-terminal region of Merlin.  
Several lines of evidence suggest that Merlin can be post-translationally modified 
through phosphorylation at specific serine residues by multiple kinases76,252-254. Phosphorylation 
of Merlin at serine residue 518 by Pak regulates Merlin activity by causing a proposed intra-
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molecular head-to-tail interaction, which causes inactivation of the protein and triggers cell 
proliferation255. Mammalian cell culture studies suggest that the closed form of Merlin is active 
and can inhibit proliferation256 whilst studies in Drosophila indicate that the open form of Merlin 
contains all necessary genetic functions257,258. Currently, it is not known whether this distinction 
between flies and mammals represent any functional difference and whether phosphorylation of 
Merlin in either context is directly correlated with its role in junction formation and polarity. 
More specifically, it is believed that loss of Merlin in human diseases can occur due to 
phosphorylation and subsequent proteasomal degradation76,252,253,255,259,260. Phosphorylation of 
Merlin at threonine 230 and serine 315 by the AKT kinase, targets Merlin for ubiquitination and 
subsequent degradation259.  Additionally, recent reports demonstrated that AKT phosphorylates 
Merlin at serine 10 that is increased upon S518 phosphorylation to enhance Merlin 
degradation252. Ultimately, loss of Merlin leads to loss of contact inhibition and 
proliferation256,261,262, properties that are utilized to differentiate between normal and cancerous 
cells making the understanding of Merlin post-translational modifications and potential effects 
on Merlin protein stability of increasing importance. Here we describe the function(s) of aPKC-
mediated phosphorylation of Merlin in regulating cell adhesion and apicobasal polarity. 
 
Results 
Merlin is required for the establishment of junctions in intestinal epithelial cells 
 Previous work establishing a role for Merlin in the development of epithelial cell 
adhesion and polarity in the stratified epithelium of the epidermis suggested that Merlin linked 
cell polarity and AJ proteins during early junctional morphogenesis84. To determine if this role of 
Merlin occurred in a broad range of epithelial tissues or was specific to stratified epithelium we 
infected the simple epithelium intestinal cell line Caco-2 with shRNA lentivirus targeting Merlin. 
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We confirmed decreased levels of Merlin by direct Western blot (Figure 22A) and found that 
cells depleted of Merlin displayed disrupted TJs and AJs as shown by staining with the TJ 
marker ZO-1 and the AJ marker E-cadherin (Figure 22B). Given this alteration in junctional 
proteins, we wanted to determine whether there was also a disruption in the formation of 
functional TJs by performing trans-epithelial resistance (TER). Similar to what was previously 
observed in keratinocytes, TJ integrity is compromised in Merlin knockdown cells as revealed by 
reduced TER (Figure 22C), indicating that Merlin is required for the formation of functional TJs 
in numerous types of epithelial cells.  
As a member of the ERM protein family, Merlin is known to convey signals from the surface 
membrane to the actin cytoskeleton, but how Merlin transmits these signals to the actin 
cytoskeleton remains unclear. Reports identify that Merlin can be involved in actin remodeling 
by association with actin regulatory proteins such as the WASP (Wiskott-Aldrich syndrome 
protein) family protein, N-WASP263 and α-catenin84. Also, the first 17 amino acids are required 
to place Merlin in an actin rich cellular compartment suggesting these amino acids may regulate 
how Merlin conveys signals to the actin cytoskeleton98. To determine if depletion of Merlin in 
simple columnar epithelial cells resulted in alterations of actin organization similar to what was 
observed in the skin, we looked at Merlin localization and actin in Caco cells with decreased 
Merlin. Decreased Merlin alters actin dynamics as compared to control (scr) cells (Figure 22D, 
middle panel). To determine if this was a direct result of decreased levels of Merlin, we 
expressed shRNA-resistant full-length Merlin. Expression of full-length Merlin led to actin 
organization at cell:cell contacts in Merlin knockdown cells (Figure 22D, bottom panel). This 
data indicates that Merlin is required for the establishment of epithelial junctions not only in a 
stratified epithelium, but also in the columnar epithelia of intestinal cells.  
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Figure 22. Merlin is required for the establishment of AJs and TJs in Caco-2 cells. A) Direct 
Western blot confirms knockdown of Merlin in Caco-2 intestinal epithelial cells. B) Loss of 
Merlin disrupts epithelial architecture as shown by staining with the TJ marker, ZO-1 (green), 
and the AJ marker, E-cadherin (red). C) TJ integrity is compromised in Merlin knockdown cells 
revealed by trans-epithelial resistance (TER). D) Merlin localization and actin organization is 
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The N-terminal region of Merlin is required for cell polarity and is phosphorylated by 
aPKC 
 Inhibition of aPKC activity impairs functional TJ formation100, which is important for 
cell polarization and epithelial function. Given that loss of either aPKC or Merlin exhibit similar 
phenotypes and that Merlin could potentially be phosphorylated at any of the four serines in the 
first 17 amino acids, we hypothesize that aPKC may have a role in Merlin-mediated cell polarity 
and junction formation by post-translational modification of Merlin. To determine if aPKC 
phosphorylates the N-terminal portion of Merlin, we performed an in vitro kinase assay. aPKC 
phosphorylates Merlin and not the closely related ERM protein family member, Ezrin, that lacks 
the unique 17 amino acids of Merlin (Figure 23A). The candidate phosphorylation sites of the 
Merlin protein at serine residues 7, 10, 12 and 13 are unique among ERM proteins and mutation 
of all four serines within this region inhibit phosphorylation of Merlin by aPKC (Figure 23A). 
The N-terminal region of Merlin is required for TJ establishment through the tethering of the 
apical protein, Par3, to the AJ protein, α-catenin; an association that must occur for the 
formation of functional junctions84. The formation of functional TJs is directly linked to cell 
polarity as TJs serve as a fence to restrict apical proteins to the apical membrane24-26.  To identify 
whether the N-terminal region of Merlin is critical for cell polarity in Caco-2 cells, we performed 
a 3D culture cyst formation assay94,165,167. Compared to empty vector control, Merlin-depleted 
(Merlin-shRNA) cells present with a multiple lumen phenotype (Figure 23B). However, this 
phenotype is rescued when full-length Merlin (Merlin FL) is expressed in these cells (Figure 
23B). A multiple lumen phenotype is seen when the same cells expressed a truncated form of 
Merlin lacking the first 17 amino acids (Merlin18-595) (Figure 23B, right panel), indicating that 
the N-terminal region is critical for the role of Merlin in cell polarity.   
 
	   79	  
 
Figure 23. The N-terminal region of Merlin is required for apicobasal polarity and is 
phosphorylated by aPKC. A) In vitro kinase assay showing phosphorylation of Merlin by 
aPKC, but not the closely related ERM protein, Ezrin (top panel). Phosphorylation of Merlin is 
inhibited when non-phosphorylatable mutations are present at S7, S10, S12, and S13. 
Phosphorylation is reduced with mutations at S12 and S13 only (bottom panel). B) 3D lumen 
formation assay indicating that the extreme N-terminal region of Merlin is required for formation 
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aPKC regulates Merlin localization and function through post-translational modifications 
To determine the specific phosphorylation site(s) of Merlin by aPKC we mutated each 
individual serine site and stably expressed an shRNA-resistant mutant construct in Caco-2 cells 
that have Merlin knockdown (Figure 24A). Actin is disrupted in cells where Merlin is unable to 
be phosphorylated at residue S13 in a similar manner as cells with knockdown of endogenous 
Merlin (Figure 24B). This suggests that the phosphorylation event on residue S13 of Merlin may 
be necessary for proper loading of the junctional polarity complex (α-catenin/Merlin/Par3) onto 
the AJ during junctional development. Also, phospho-deficient mutants of residues S7, S10, or 
S12 results in decreased junctional integrity as seen by TER (Figure 24C). This suggests that 
phosphorylation at these residues may be critical for the release of the aPKC/Par3 complex to the 
apical membrane for the formation of TJs. From this, we see that aPKC phosphorylation of 
Merlin can possibly alter the function of Merlin, an event that has the potential to cause 
interference with cell adhesion and promote Merlin-mediated tumorigenesis. 
It is well documented that Merlin mediates contact inhibition of proliferation256,261,264-266, 
the ability of cells to stop proliferating when they come in contact with one another. Loss of 
contact inhibition can occur when tumor cells circumvent the innate mechanisms that cells use to 
control proliferation, such as growth control signals from neighboring cells. Several mechanisms 
exist for how Merlin regulates contact inhibition in cultured mammalian cells, including 
suppression of Rac recruitment to the plasma membrane261 and through its interaction with the 
transmembrane receptor, CD44256. Loss of Merlin function contributes to tumor initiation and/or 
progression due to the inability of cells to establish stable AJs, which leads to the loss of contact 
inhibition.  However, it is unknown whether phosphorylation of Merlin at its N-terminal region 
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Figure 24. aPKC regulates Merlin localization and function through post-translational 
modifications. A) Western analysis of re-expression of Merlin point mutants in Caco-2 cells. B) 
Merlin (green) and actin (red) staining in cells expressing Merlin point mutants. Merlin 
localization and actin organization are altered in cells harboring a Merlin mutation at S13 and at 
all four serine sites in the N-terminal region of Merlin. C) TER readings for Merlin point 
mutants. TJ integrity is compromised in Merlin N-terminal mutations at S7, S12 and S13. 
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is critical for its role in mediating contact inhibition. To address the potential effect 
phosphorylation may have on Merlin-mediated contact inhibition, we performed a growth curve 
assay where cells were plated and counted every six hours up to confluency and post confluency. 
We identified that Merlin knockdown in Caco-2 cells did exhibit loss of contact-dependent 
inhibition of proliferation and expression of full-length sh-RNA resistant Merlin rescues the loss 
of contact inhibition (Figure 25A). We also observed a loss of contact inhibition when all 
phosphorylation is blocked at the four serines at residues S7, S10, S12, and S13 of the N-
terminal region of Merlin (Figure 25B); this is similar to knockdown of Merlin. Loss of contact 
inhibition is observed when S12 and S13 are unable to be phosphorylated (Figure 25B), 
suggesting that these phosphorylation events may be critical for the stabilization of AJ-mediated 
adhesion by Merlin. Our evidence does not currently support a role for S10 phosphorylation in 
Merlin-mediated contact inhibition. These data suggest that aPKC phosphorylation of Merlin at 
S12 and S13 could regulate the role of Merlin in contact inhibition and AJ-mediated adhesion.  
 
Discussion 
 The Nf2 tumor suppressor gene-encoded protein, Merlin, has been implicated in the 
establishment and maintenance of epithelial junctions84,94 much like the closely related ERM 
(ezrin, radixin, moesin) protein family. However, the mechanism that regulates Merlin 
coordination of epithelial junction development is unclear.  Herein we described a role for aPKC	  phosphorylation	  of	  the	  N-­‐terminal	  region	  of	  Merlin	  that	  regulates	  its	  role	  in	  cell	  adhesion	  and	  polarity.	  To	  examine	  the	  function	  of	  Merlin	  in	  adhesion	  and	  polarity,	  we	  utilized	  the	  polarized	  epithelial	  cell	  line,	  Caco-­‐2,	  due	  to	  the	  potential	  dynamic	  nature	  of	  Merlin  
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Figure 25. Post-translational modification of the N-terminus of Merlin regulates its role in 
contact inhibition. A) Growth curve assay of scr (blue), Merlin-shRNA (red) and Merlin full-
length reexpression (pink). Full-length reexpression rescues the loss of contact inhibition 
observed in Merlin knockdown cells. B) Growth curve for Merlin point mutants at S10 (brown), 
S12 (green), S13 (purple) and S7/10/12/13 (orange). Loss of contact inhibition is observed when 
all four serinces are unable to be phosphorylated. Point mutations at S12 and S13 also lose 
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phosphorylation	  by	  aPKC. We found that Merlin	  knockdown	  alters	  actin	  organization	  at	  the	  cell	  membrane.	  This	  evidence	  is	  in	  line	  with	  previous	  reports	  that	  endogenous	  Merlin	  decorates	  the	  cortical	  actin	  cytoskeleton98	  and	  it	  is	  required	  to	  link	  α-­‐catenin	  to	  Par384.	  Here	  we	  show	  that	  aPKC	  phosphorylates	  the	  extreme	  N-­‐terminal	  region,	  the	  first	  17	  amino	  acids,	  of	  Merlin	  that	  is	  required	  for	  its	  association	  with	  α-­‐catenin	  at	  the	  AJ	  during	  junction	  development84.	  	  We	  have	  identified	  a	  multi-­‐step	  process	  in	  junctional	  development	  controlled	  by	  aPKC	  phosphorylation	  of	  the	  N-­‐terminal	  region	  of	  Merlin.	  The	  first	  step	  elicits	  proper	  loading	  of	  the	  junctional	  polarity	  complex	  (α-­‐catenin/Merlin/Par3)	  onto	  the	  AJ.	  When	  phosphorylation	  of	  Merlin	  is	  inhibited	  at	  S13,	  actin	  is	  disorganized	  suggesting	  compromised	  junction	  integrity.	  Merlin	  phosphorylation	  at	  residues	  S7,	  S10	  and	  S12	  does	  not	  affect	  actin	  dynamics	  and	  therefore	  suggest	  that	  these	  phosphorylation	  sites	  are	  not	  required	  for	  the	  establishment	  of	  AJ	  adhesions.	  A	  second	  step	  involving	  release	  of	  Par3/aPKC	  to	  the	  apical	  domain	  for	  formation	  of	  functional	  TJs	  possibly	  occurs	  by	  phosphorylation	  of	  Merlin	  at	  residue	  S7	  and/or	  S12	  by	  aPKC.	  This	  is	  identified	  through	  the	  inhibition	  of	  formation	  of	  functional	  TJs	  in	  cells	  where	  Merlin	  cannot	  be	  phosphorylated	  at	  residue	  S7	  and	  S12.	  	  This	  provides	  new	  evidence	  for	  a	  step-­‐wise	  process	  of	  Merlin	  phosphorylation	  since	  actin	  is	  organized,	  but	  functional	  TJ	  development	  is	  impaired	  when	  Merlin	  S7	  and	  S12	  phosphorylation	  is	  blocked.	  Thus,	  it	  is	  possible	  that	  multiple	  phosphorylation	  events	  must	  occur	  for	  release	  of	  aPKC/Par3	  to	  the	  apical	  membrane	  to	  establish	  TJs.	  Reduced	  TER	  in	  cells	  where	  Merlin	  cannot	  be	  phosphorylated	  at	  residue	  S13	  can	  be	  attributed	  to	  the	  observation	  that	  these	  cells	  do	  not	  form	  functional	  AJs.	  However,	  we	  cannot	  rule	  out	  any	  additional	  phosphorylation	  events	  that	  might	  be	  required	  for	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My dissertation work uncovers novel roles for the FERM domain proteins, PTPN14 and 
Merlin, in regulating cell adhesion, polarity and lumen formation. FERM domains exist in a 
variety of mammalian proteins, with the central function of the domain acting as a linker 
between the plasma membrane and cytoskeletal structures at distinct cellular locations63. Both 
PTPN14 and Merlin exhibit membrane localization in cultured epithelial cells, but the 
endogenous function of PTPN14 remains elusive and the mechanism of Merlin coordination of 
epithelial junction development is unclear.  Our new data contributes to these gaps in knowledge 
increasing our understanding of AJ-mediated adhesion and identifying potential future 
therapeutic avenues in multiple cancers types.  
 The non-receptor tyrosine phosphatase, PTPN14, was first discovered in 1995 as a FERM 
protein family member64 and years later the crystal structure was elucidated to uncover unique 
structural features of PTPN14 among the PTP family members268. In recent years, there has been 
an explosion of literature focusing on potential roles of PTPN14 in organ development65, 
adhesion269,270, motility67, proliferation71,163 and cancer68,271,272. However, the endogenous 
functions of PTPN14 still remain a mystery aside from the fact that it harbors phosphatase 
activity. One group found that the AJ protein, β-catenin, is a substrate of PTPN14 in vitro67, but 
the tyrosine residue was left unidentified. In addition, there is no evidence of any opposing 
kinase(s) of PTPN14. As modeled in Figure 26, we discovered that PTPN14 opposes Src kinase 
activity at β-cateninY654 to precisely regulate AJ-mediated adhesion and ex vivo lumen 
formation. PTPN14 activity is necessary for the formation of functional AJs and TJs, a required 
feature for a cell to possess proper apicobasal polarity. In cells with established epithelial 
junctions, decreased PTPN14 activity increases E-cadherin membrane movement thereby 
weakening the AJ. Curiously, the stabilization of E-cadherin in the primordial lumen 
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Figure 26. PTPN14 is a major regulator of AJ-mediated adhesion. In established epithelia, 
PTPN14 opposes Src-mediated β-catenin-Y654 phosphorylation to regulate AJ adhesion. Our 
data demonstrates that decreased PTPN14 increases phosphorylation of β-catenin-Y654 and E-
cadherin membrane movement potentially as a complex with β-catenin. Destabilization of E-
cadherin in the absence of PTPN14 causes cells to lose functional AJs and TJs to ultimately 
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 of three-dimensional intestinal cysts by PTPN14 is necessary for the formation of a single 
central lumen. We have identified an E-cadherin bridge between two cells prior to primordial 
lumen formation that is abolished when cells are depleted of PTPN14. Consequently, when 
adhesion is altered at an early stage, cells cannot form functional AJs and TJs, thereby never 
establishing apicobasal polarity that is required for lumen morphogenesis. Although this has 
never been described before, it is interesting to speculate that E-cadherin accumulation at either 
end of this “bridge” would be controlling the mechanical forces required to open up the luminal 
space. To date, the inability to form a lumen is seen in only one other recorded incidence, when 
Ezrin function is eliminated by the expression of a dominant-negative version of Ezrin (EzrinΔact) 
that cannot bind to nor stabilize actin94. This was attributed to the lack of apical integrity 
mediated by Ezrin, but we also know that apicobasal polarity is regulated by the fence function 
of the TJ. Prior reports do identify a role for TJ proteins in the increase of internal fluid pressure 
to facilitate luminal expansion273,274. However, when TJs are compromised, the observed 
outcome is a formation of multiple lumens, which indeed is a feature of loss of cell polarity due 
to mitotic spindle misorientation84. Therefore, our data demonstrates that the underlying reason 
for a no lumen phenotype is distinct from that of a multiple lumen. We have shown that adhesion 
is tightly regulated by the AJ during the early stages of primordial lumen formation and since the 
formation of functional TJs is dependent on functional AJs, PTPN14 knockdown cells have 
chronic weakening of AJs and never form a lumen in 3D. This is the first evidence highlighting a 
critical role of PTPN14 and AJ-mediated adhesion in lumen morphogenesis.   
Observations that PTPN14 is mutated or levels are altered in colorectal, breast, and 
pancreatic cancer suggest that PTPN14 may be important for the maintenance of epithelial 
tissues. The exact threshold at which a decrease or increase in PTPN14 activity alters cell 
adhesion is yet to be determined. There is evidence to suggest that PTPN14 has oncogenic 
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potential in endothelial163 and epithelial cells65,270. However, there is also data demonstrating that 
PTPN14 can act as a tumor suppressor65,66,72,206,220,271,272, suggesting that the level of PTPN14 
activity is critical to maintain the balance of cellular homeostasis. We demonstrate that over time, 
decrease of PTPN14 activity primes cells to undergo an EMT transcriptional response, complete 
with repression of E-cadherin possibly through Snail2/Slug, loss of collective cell migration and 
loss of contact inhibition of proliferation. At this time, we cannot rule out alterations of any 
additional proteins that may contribute to the mesenchymal characteristics of these cells. 
However, we have established that EMT observed in PTPN14 knockdown cells is independent of 
the TGFβ and Hippo signaling pathways. Additionally, Notch signaling is activated in cells with 
decreased PTPN14 and Notch was previously shown to directly bind and activate the Snail2/Slug 
promoter217. Both TGFβ and Hippo are implicated in regulating EMT in multiple cell types 
coupled with either an increase or decrease in PTPN14 activity65,71. We have not observed any 
transcriptional effects on TGFβ or Yap pathway targets in our work in intestinal epithelial cells. 
Interestingly, PTPN14 is shown to translocate to the nucleus in proliferating vascular endothelial 
cells163, but we have been unable to observe nuclear PTPN14 in semi-confluent or confluent 
monolayers of epithelial cells. This could suggest that PTPN14 may have precise tissue-specific 
roles that could be modulated by other pathways acting upon PTPN14 transcription or post-
translational regulation of PTPN14 by other proteins. We have yet to learn what protein(s) 
regulate PTPN14 activity and expression, which might provide insight into how PTPN14 alters 
cell adhesion to initiate or accelerate disease progression.  
Two chapters of my dissertation highlight the significance of PTPN14, a protein that is 
relatively poorly understood in terms of endogenous function and regulation. Our work has 
uncovered novel roles for PTPN14 in regulating AJ-mediated adhesion through stabilization of 
E-cadherin/β-catenin. Over time the reduced activity of PTPN14 causes an EMT response in 
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cultured cells. Our potential future research for PTPN14 could unfold in multiple ways 
including; 1) investigating the fine-tuning regulation of PTPN14 phosphatase activity at the AJ 
and 2) the big picture impact of PTPN14 loss or reduced activity has on disease initiation and/or 
progression.  
 
Fine-tuning PTPN14 activity at the AJ 
 Although we now have a better understanding of a mechanism that is controlled by 
PTPN14 activity at the AJ, questions remain on what proteins might be regulating PTPN14.  
During lumen morphogenesis, what triggers PTPN14 to dephosphorylate β-catenin Y654 thereby 
stabilizing the primordial cell contact to facilitate the formation of a single lumen? Since tissue 
morphogenesis is contingent on collective cell movements275-280 and mechanical cues281-285, 
perhaps there are mechanical forces at play that intrinsically signal to activate PTPN14. Studies 
in C. elegans identify a need for continuous Notch signaling, which controls the Rho kinase 
LET-501 to induce actomyosin-mediated contraction of the apical lumen in the developing 
vulval tube286. It is possible that PTPN14 may be responding to mechanical forces set in motion 
by Notch signaling or vice versa. Future work must be done to gain a firm understanding of 
exactly what mechanical forces drive the opening of the primordial cell contact, the potential 
critical first step to forming a single lumen.   
 Conversely, what is regulating PTPN14 activity in established epithelia? One could 
hypothesize that there is a built-in feedback loop between PTPN14 and its opposing kinase, Src, 
during the maintenance of established epithelial adhesion. Increased growth-factor dependent 
signaling of Src reduces adhesion159, but how PTPN14 responds to this increase in Src is 
unknown. Also of interest is whether or not PTPN14 is cooperating with additional AJ 
phosphorylation events in the establishment and maintenance of epithelial adhesion in tissue 
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homeostasis. Does PTPN14 reside at the AJ permanently or is it a transient component that is 
only recruited to the AJ to dephosphorylate β-catenin and possibly other AJ proteins under 
certain conditions? Two examples of AJ proteins that are regulated by tyrosine phosphorylation 
to stabilize the AJ are E-cadherin and p120-catenin. E-cadherin tyrosine phosphorylation at 
residues 753-755 by the Src kinase facilitates ubiquitination and subsequent docking of the E3-
ligase Hakai287. In turn, this ubiquitination leads to internalization of E-cadherin and disruption 
of the AJ288. It would be interesting to examine the phosphorylation state of E-cadherin Y733-
735 in Caco-2 cells and compare it to what we observe with regards to PTPN14 mediated AJ 
stabilization to obtain a better picture to how Src activity is opposed at the AJ. Src also 
phosphorylates p120-catenin on eight tyrosine residues of its N-terminal region and this event 
serves as recruitment for interacting proteins carrying SH2 domains289,290. There are instances 
where p120-catenin phosphorylation can increase its binding affinity to cadherin although this 
increase is not always observed291. This is important considering that p120 can protect E-
cadherin from internalization, which has significant impacts on AJ dynamics158. These are a few 
examples that provide strong evidence that phosphorylation switches play an important role in 
the stabilization of the AJ, but common biochemical techniques can limit the scope of 
phosphorylation events at the AJ. Phospho-proteomic data have identified multiple 
phosphorylated serine/threonine and tyrosine residues of AJ proteins292. This approach could 
serve as a first step to help increase our knowledge of phosphorylation switches that regulate the 
AJ. A future challenge will be to take a comprehensive look at the phosphorylation network at 
the AJ with other regulatory switches to gather a complete understanding of how signaling and 
force regulates AJ dynamics.  
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PTPN14 in disease initiation and progression 
 We are particularly interested in the function(s) of PTPN14 in pathological conditions 
such as CRC. We are beginning to work with CRC patient-derived mutations in our cell culture 
model to understand if the mutations have similar effects on E-cadherin membrane mobility as 
reduced PTPN14 activity. Wang, et al discovered a distribution of PTPN14 mutations in CRC 
patients with multiple mutations uncovered in the non-conserved interlinking region, a single 
mutation in the FERM domain and a single mutation in the PTP domain66. The two mutations 
found in the FERM (L56M) and PTP (T1068M) domains are of interest to us since these are 
conserved regions of the PTPN14 protein. With the help of Dr. Stefan Arold (King Abdullah 
University of Science and Technology), we modeled these CRC patient-derived mutations to 
understand the potential biological ramifications they may have on protein structure and function. 
Possible effects of the CRC mutation T1068M (Figure 27A) have been assessed previously as 
having no potential effect on protein function since this residue sticks out into solvent on the 
opposite face from the active phosphatase site at C1121268. As such, we do not anticipate that this 
mutation has any detrimental effects on protein structure or function. However, the story is quite 
different for the CRC patient-derived mutation in the FERM domain at L56M. From the 
structural modeling, we have hypothesized that the L56M mutation in the FERM domain has the 
potential to interfere with possible binding partners due to the nature of a the mutated proline 
residue sticking out into the binding pocket between the F1 and F2 lobes of the FERM domain 
(Figure 27B). Through bioinformatics approaches, with our collaborator, Dr. Bin Liu (MD 
Anderson Cancer Center), we have discovered an additional CRC patient-derived mutation at 
L904P that could lead to a local or even global destabilization of the PTP domain (Figure 27C). 
A future challenge is to determine if these mutations cause weakening of AJ-mediated adhesion 
similar to  decreased PTPN14 and if they increase signaling pathways, such as Notch, that are 
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Figure 27. Structural modeling of PTPN14 CRC patient-derived mutations. A) The PTP 
domain mutation T1068M sticks out into solvent suggesting no potential effect on protein 
structure and stability. Wild-type residues are colored with carbons in pink and mutant carbons 
are in grey. B) FERM domain mutation L56M sticks out into a potential binding pocket between 
the F1 and F2 lobes of the FERM domain presenting a potential inhibition of binding partners. 
Wild-type residues are colored with carbons in pink and mutant carbons are in white. C) The 
L904P mutation is situated at the C-terminal end of the first α helix (α1) of the PTP domain. 
This mutation may produce strain on the loop region and C terminal end of α1 leading to 
potential destabilization of the PTP domain. Wild-type residues are colored with carbons in grey 
and mutant carbons are in yellow. Modeling courtesy of Dr. Stefan Arold (KAUST) 
key regulators of disease initiation and/or progression. 
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 Ultimately, the desire is to study the impact of PTPN14 loss in human disease. 
Unfortunately at this time there is no PTPN14 conditional knockout mouse models in existence. 
To this end, a potential future research endeavor of this project is to create a mouse model to 
study PTPN14 function in vivo. We hypothesize that if a complete knockout mouse of PTPN14 
is not embryonic lethal, then these mice will possibly present with development defects such as 
decreased barrier function of the skin and abnormalities in organs that form tubes such as the 
intestine, kidney and mammary gland. This hypothesis takes into consideration the importance of 
PTPN14 in establishing adhesive contacts in the early stages of lumen morphogenesis. There is a 
possibility that PTPN14 knockout mice could have defects, but ones that are not life threatening. 
If this is the case, a conditional knockout of PTPN14 could be utilized to selectively target 
tissues that have high expression of PTPN14, such as brain, cardiac and intestinal tissues. The 
hypothesis would then be that adhesive contacts would weaken and gradually cause sensitization 
of cells to undergo EMT, similar to what we have observed in our cell culture model. Another 
viable option would be a xenograft model where severely compromised immunodeficient (SCID) 
mice are injected with PTPN14-deficient cells and ask whether metastasis occurs. Dasatinib 
treatment could also be employed in this model to identify if the response is similar to what is 
seen in cultured cells. In addition, this system would allow a tool to express our patient-derived 
mutations to determine if these mutations affect the invasive potential of the cells. These data 
could provide substantial evidence for the function of PTPN14 in vivo and for the role it has in 
regulating tumor initiation and/or progression. 
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Merlin: Adhesion, polarity and tumor progression 
 The Nf2-encoded protein, Merlin is a classical tumor suppressor that when mutated or 
inactivated leads to familial schwannomas and meningiomas293. Although not as prevalent, 
mutations causing loss of NF2 function in non-nervous system cancers have been reported, such 
as CRC294, mesotheliomas78,295,296, prostate cancer297, melanoma and thyroid cancer298. Since 
there is not a high prevalence of Nf2 mutations in non-nervous cells it raises the possibility that 
Merlin can be inactivated at the post-translational level. It is well documented that Merlin can be 
post-translationally modified, but how this affects its roles in regulating contact-dependent 
inhibition of proliferation, cell polarity and adhesion is poorly understood. Merlin is necessary to 
bridge the AJ protein, α-catenin, to the apical protein, Par3, for the establishment of functional 
junctions in epithelial adhesive contacts84. Furthermore, the extreme N-terminal region of Merlin 
is required for this interaction. Consequently, loss of Merlin or lack of its N-terminal region 
impedes the formation of functional TJs and proper apicobasal polarity.  
As modeled in Figure 28, we discovered that aPKC phosphorylates serine sites in the 
unique N-terminal region of Merlin in a step-wise fashion to regulate its function in establishing 
junction-mediated adhesion and polarity. The first step includes loading of the junctional polarity 
complex onto the AJ followed by a second phosphorylation to release Par3 from to AJ to the 
apical membrane for the formation of TJs. Phosphorylation of Merlin S13 promotes actin 
organization, formation of functional TJs and Merlin localization at the membrane. This is the 
first potential step that is required for proper loading of Merlin onto the AJ during the 
development of functional junctions, which is why we see impaired TJs since TJ formation is 
dependent on the establishment of functional AJs. Phosphorylation of Merlin S7 and S10 are also 
required for the formation of functional TJs, but are not essential for the organization of actin 
and Merlin localization at the membrane, making them likely candidates as phosphorylation sites  
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Figure 28. Post-translational modification of the N-terminal region of Merlin by aPKC 
regulates its function in the establishment of junctions and apicobasal polarity. Our data 
provides evidence of a multi-step process in junctional development controlled by aPKC 
phosphorylation of the N-terminal region of Merlin. An initial phosphorylation at S13 (1) is 
required to load the junctional polarity complex (α-catenin/Merlin/Par3) onto the AJ. A second 
phosphorylation event (2) possibly at S7 and/or S12 releases Par3/aPKC to the apical domain for 
the formation of functional TJs. Phosphorylation of the N-terminal region of Merlin by aPKC is 
necessary for Merlin localization at the membrane, actin organization, the establishment of 
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required for localization of Par3 to the apical membrane to facilitate TJ formation. However, we 
cannot be certain that these are the only phosphorylation events required for Merlin function in 
regulating junctional development. The FERM domain and C-terminal tail of Merlin can 
associate to change the accessibility to its binding partners61. Early reports described that 
phosphorylation of Merlin at S518 is shown to open the protein thereby leading to its 
inactivation299,300. Later this was shown to be a static process whereby Merlin is not fully open or 
closed, but tends to vary in degrees of openness301,302. This suggests that S518 phosphorylation 
has the ability to increase the interaction of the FERM and C-terminal tail of Merlin to leave it in 
a fairly closed and inactive state away from the cell membrane302. Membrane localization of 
Merlin is only lost when Merlin cannot be phosphorylated at S13, suggesting that S518 
phosphorylation may not act in concert with additional phosphorylation events occurring during 
junctional development. To test this, we could express the Merlin S7 and S13 non-
phosphorylatable mutants and perform Western analysis at different time points in junctional 
development and observe whether the phosphorylation state of Merlin-S518 is altered. 
Nevertheless, we do see that phosphorylation of the N-terminal region of Merlin has an effect on 
growth control and contact-dependent inhibition of proliferation, a hallmark of tumorigenesis.  
Acquisition of our functional data has led us to look specifically at in vitro 
phosphorylation of Merlin by aPKC. We currently have six GST Merlin protein constructs to use 
as substrates for aPKC: GST-Merlin, GST-Merlin-S7A, GST-Merlin-S10A, GST-Merlin-S12A, 
GST-Merlin-S13A and GST-Merlin-Δ1-17. Due to recent literature indicating similar functions 
for the aPKCι and aPKCζ isoforms, we are performing these kinase assays to possibly identify 
isoform-specific functions for aPKC in Merlin phosphorylation. Based on our functional data, it 
is possible that we will observe multiple sites of Merlin phosphorylation by the different aPKC 
isoforms. Future experiments could then be geared towards mechanistically showing at which 
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point in junctional development each phosphorylation event occurs on the N-terminal region of 
Merlin. This could include co-immunoprecipitation experiments at multiple time points during 
junctional development similar to what was performed with PTPN14 (See Figure 5). With this, 
the development of phospho-specific antibodies against each serine site in the N-terminal region 
of Merlin would be useful for future analysis. Also, we plan to address if Merlin still interacts 
with polarity proteins when the N-terminal region is unable to be phosphorylated. Preliminary 
data suggests that phosphorylation of specific serine(s) may be critical for the interaction of 
Merlin with aPKC and Par3. 
Merlin loss causes the formation of multiple lumens in 3D, which can be restored with 
full length Merlin. Interestingly, our data and other reports show that this rescue of a single 
lumen is dependent on the N-terminal region of Merlin94. We are currently determining if any of 
our candidate serine sites in this N-terminal region must be phosphorylated to ensure the 
formation of a single lumen. From our data, we hypothesize that S7 or S13 phosphorylation will 
be required for the formation of a single lumen. Serine 12 may also be important due to the close 
proximity to S13, although we have yet to see similarities between the two sites. This hypothesis 
stems from the fact that S7 and S13 phosphorylation are required for the establishment of 
functional TJs that serve as a fence to divide the apical and basal membranes, a prerequisite for 
apicobasal polarity and ultimately, lumen morphogenesis.  
Furthermore, we are interested in identifying the role of the Merlin/aPKC/Par3 polarity 
complex in tumor progression. Loss of Merlin in cultured cells leads to contact-dependent 
inhibition of proliferation, properties that are utilized to differentiate between normal and 
cancerous cells. Since loss of Merlin in epithelial cells alter Par3 and aPKC localization, we are 
interested in examining the pathway that governs cell polarity to determine if these proteins act 
in concert with Merlin to facilitate proper epithelial cell polarity and thereby avoid tumorigenic 
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behavior. Specifically, we are interested in understanding the role of the Merlin/Par3/aPKC 
polarity complex in the regulation of Nf2 tumors. We seek to understand if localization of Par3 
and aPKC is altered in Nf2 tumor cells and tissues to determine their roles in tumor progression.  
We have both human and mouse Nf2-deficient schwannoma tumor cells (HEI193 and SC4 cells) 
where we can express full-length Merlin via lentiviral infection into these Schwann cells to 
determine if this relocalizes the Par3/aPKC complex. We hypothesize that Par3 and/or aPKC will 
not localize to proper membrane compartments in Nf2-deficient cells. This result would 
correspond with what we have observed in epithelial tissues and indicate that membrane 
localization of Par3 and aPKC is dependent on Merlin. If one of the N-terminal serine Merlin 
point mutants blocks binding to either Par3 or aPKC, we could use that mutant to determine if re-
establishment of polarity in Nf2 mutant Schwann cells can restore Schwann cell function. 
Alternatively, Par3 and aPKC could localize to their corresponding membrane compartments in 
Nf2-deficient cells, suggesting that the function of these proteins in Nf2 tumor cells is not 
dependent on mis-localization, but instead occurs through other functions.  
This work uncovers novel roles for the FERM proteins, PTPN14 and Merlin, in 
regulating epithelial cell adhesion and apicobasal polarity. We highlight the importance of 
PTPN14 in 3D lumen morphogenesis, regulating the stability of the AJ protein, E-cadherin. E-
cadherin is a major component of the AJ that is required for stable cell adhesive contacts. E-
cadherin forma a bridge at the primordial contact that is dependent on PTPN14 and the 
phosphorylation state of β-cateninY654. As the primordial lumen opens to reveal an apical 
membrane facing the inner luminal surface, E-cadherin clusters at either end of the primordial 
contact as if it is needed to mechanically push open the luminal space and maintain cell adhesion. 
Although not fully understood, this process is dependent on PTPN14 activity; otherwise cells fail 
to form a lumen in 3D. This makes PTPN14 a significant contributor to the development of ex 
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vivo lumen morphogenesis. Conversely, Merlin is required to establish apical identity following 
the initial primordial cell contact. This is done so through phosphorylation of the N-terminal 
region of Merlin by aPKC. Two phosphorylation events could occur to load Merlin onto the AJ 
and release Par3 and aPKC from the AJ to the TJ.  If these two events do not occur then polarity 
is disrupted and cells will form a multiple lumen in 3D. The difference in luminal phenotypes 
with decreased PTPN14 and Merlin highlight the importance of the early establishment of cell 
adhesion and the coordination of apicobasal polarity, respectively. This model provides insight 
into how the formation of biological tubes is regulated during normal development. 
Also, we have identified that PTPN14 and Merlin are required for maintaining adhesion 
in established epithelia. A balance of PTPN14 activity is necessary for the maintenance of 
adhesion through dephosphorylation of β-cateninY654. PTPN14 and Merlin depletion leads to 
the loss of functional junctions, which is indicative of loss of barrier function. Defects in 
epithelial barrier function are observed in chronic conditions that can lead to intestinal 
inflammatory disease and colitis-associated cancers129. Importantly, over time decreased 
PTPN14 causes cells to undergo a transition to a mesenchymal phenotype indicating that 
prolonged reduced activity of PTPN14 can initiate tumor progression. This makes PTPN14 of 
clinical relevance as a potential drug target for inflammatory diseases of the intestines and 
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